Institut de Médecine Tropicale Anvers
  Départements - Microbiologie   - Publications   
Recherche
Nouvelles
Contacts
Emploi
Voyages
Liens utiles
 
Nederlands
Français
English
 
 Print

Full-text papers (i.e. abstracts not included) published by members of this department since 1998 are listed below. The references are arranged by year of publication, then alphabetically by first authors' name. This list was last updated on November 13th, 2008.

For a survey of all ITG publications, consult the ITG Staff Publications (1933- ) database.

2009

  • Affolabi D. Development of simple and inexpensive tools for the control of mycobacterial diseases in a low-resource country [dissertation]. Antwerp: University of Antwerp, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, 2009: 210 pp.
  • Affolabi D, Anyo G, Faïhun F, Sanoussi N, Shamputa IC, Rigouts L, Kestens L, Anagonou S, Portaels F. First molecular epidemiological study of tuberculosis in Benin. Int J Tuberc Lung Dis 2009; 13(3): 317-322.
  • Affolabi D, Faïhun F, Sanoussi N, Anyo G, Shamputa IC, Rigouts L, Kestens L, Anagonou S, Portaels F. Possible outbreak of streptomycin-resistant Mycobacterium tuberculosis Beijing in Benin. Emerg Infect Dis 2009; 15(7): 1123-1125.
  • Amornkul PN, Vandenhoudt H, Nasokho P, Odhiambo F, Mwaengo D, Hightower A, Buvé A, Misore A, Vulule J, Vitek C, Glynn J, Greenberg A, Slutsker L, De Cock KM. HIV prevalence and associated risk factors among individuals aged 13-34 years in rural western Kenya. PLoS ONE 2009; 4(7): e6470.
  • Best I, López G, Verdonck K, González E, Tipismana M, Gotuzzo E, Vanham G, Clark D. IFN-gamma production in response to Tax 161-233, and frequency of CD4+ Foxp3+ and Lin-HLA-DR high CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population [electronic only]. Immunology 2009; 128(1(pt2)): e777-e786.
  • Buvé A. Waar en hoe ontstond de hiv-pandemie? Tijdschr Geneeskd 2008; 64(16): 804-806.
  • de Lourdes Shikama M, Ferro E RR, Conceiçao Martins M, Saraiva Giampaglia CM, Siqueira Oliveira R, Silva RFAM, Ferro E P, da Silva Telles MA, Martin A, Palomino JC. Rapid detection of resistant tuberculosis by nitrate reductase assay performed in three settings in Brazil. J Antimicrob Chemother 2009; 64(4): 794-796.
  • Defraye A, Crucitti T, Ducoffre G, Mak R, Sasse A. Incidence des infections à Neisseria gonorrhoeae en Belgique: tendances 2000-2006. Rev Méd Brux 2009; 30(2): 93-98.
  • Delvaux T. Linking sexual and reproductive health and HIV services: from needs to feasibility and evidence of benefits [dissertation]. Gent: Universiteit Gent, Faculteit Geneeskunde en Gezondheidswetenschappen, 2009: 178 pp.
  • Delvaux T, Elul B, Ndagije F, Munyana E, Roberfroid D, Asiimwe A. Determinants of nonadherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Rwanda. J Acquir Immun Defic Syndr 2009; 50(2): 223-230.
  • Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RPG, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, McNeeley DF. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360(23): 2397-2405.
  • Dieltjens T, Heyndrickx L, Willems B, Gray E, Van Nieuwenhove L, Grupping K, Vanham G, Janssens W. Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies. Retrovirology 2009; 6(113): 13.
  • Dieltjens T, Loots N, Vereecken K, Grupping K, Heyndrickx L, Bottieau E, Vanham G, Davis D, Janssens W. HIV type 1 subtype A envelope genetic evolution in a slow progressing individual with consistent broadly neutralizing antibodies. AIDS Res Hum Retroviruses 2009; 25(11): 1165.
  • Durnez L, Sadiki H, Katakweba A, Machang'u RR, Kazwala RR, Leirs H, Portaels F. The prevalence of Mycobacterium bovis-infection and atypical mycobacterioses in cattle in and around Morogoro, Tanzania. Tropical Animal Health and Production 2009; 41(8): 1643-1659.
  • Durnez L, Stragier P, Roebben K, Ablordey A, Leirs H, Portaels F. A comparison of DNA extraction procedures for the detection of Mycobacterium ulcerans, the causative agent of Buruli ulcer, in clinical and environmental specimens. J Microbiol Meth 2009; 76(2): 152-158.
  • Eddyani M. Development of better methods for the laboratory diagnosis of Mycobacterium ulceran disease (Buruli ulcer) and search for environmental reservoirs of Mycobacterium ulcerans [dissertation]. Antwerpen: Universiteit Antwerpen, Faculteit Farmaceutische, Biomedische en Diergeneeskundige Wetenschappen, 2009: 183 pp.
  • Eddyani M, Fraga AG, Schmitt F, Uwizeye C, Fissette K, Johnson C, Aguiar J, Sopoh G, Barogui Y, Meyers WM, Pedrosa J, Portaels F. Fine-needle aspiration, an efficient sampling technique for bacteriological diagnosis of nonulcerative Buruli ulcer. J Clin Microbiol 2009; 47(6): 1700-1704.
  • Elul B, Delvaux T, Munyana E, Lahuerta M, Horowitz D, Ndagije F, Roberfroid D, Mugisha V, Nash D, Asiimwe A. Pregnancy desires, and contraceptive knowledge and use among prevention of mother-to-child transmission clients in Rwanda. AIDS 2009; 23(Suppl.1): S19-S26.
  • Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Sattentau Q, Schuitemaker H, Sutthent R, Wrin T, Scarlatti G. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS ONE 2009; 4(2): 12 pp.
  • Freeman EE, White RG, Bakker R, Orroth KK, Weiss HA, Buvé A, Hayes RJ, Glynn JR. Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine 2009; 27(6): 940-946.
  • Hurtado Ortiz R, Aguilar Leon D, Orozco Estevez H, Martin A, Luna Herrera J, Flores Romo L, Portaels F, Hernandez Pando R. Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas. Clin Exp Immunol 2009; 157(2): 271-281.
  • Huygen K, Adjei O, Affolabi D, Bretzel G, Demangel C, Fleisher B, Johnson RC, Pedrosa J, Phanzu DM, Phillips RO, Pluschke G, Siegmund V, Singh M, van der Werf TS, Wansbrough-Jones M, Portaels F. Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol 2009; 198(2): 69-77.
  • Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, Jaye A, Cotten M, Vanham G, McConkey SJ, Rowland-Jones S, Janssens W. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in The Gambia and emergence of drug-resistant variants. J Clin Microbiol 2009; 47(7): 2200-2208.
  • Jallow S, Vincent T, Leligdowicz A, De Silva T, Van Tienen C, Alabi A, Sarge-Njie R, Aaby P, Corrah T, Whittle H, Jaye A, Vanham G, Rowland-Jones S, Janssens W. Presence of a multidrug-resistance mutation in an HIV-2 variant infecting a treatment-naive individual in Caio, Guinea Bissau. Clin Infect Dis 2009; 48(12): 1790-1793.
  • Jenabian MA, Saïdi H, Charpentier C, Van Herrewege Y, Son JC, Schols D, Balzarini J, Vanham G, Bélec L. In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). Journal of Antimicrobial Chemotherapy 2009; 64(6): 1192-1195.
  • Kam KM, Yip CW, Tang HS, Van Deun A. Bulk acid-fast staining of sputum smears: time to end a taboo. Int J Tuberc Lung Dis 2009; 13(9): 1119-1123.
  • Kendall EA, González E, Espinoza I, Tipismana M, Verdonck K, Clark D, Vermund SH, Gotuzzo E. Early neurologic abnormalities associated with human T-cell lymphotropic virus type 1 infection in a cohort of Peruvian children. Journal of Pediatrics 2009; 155(5): 700-706.
  • Kibadi K, Boelaert M, Kayinua M, Minuku JB, Muyembe-Tamfum JJ, Portaels F, Lefèvre P. Therapeutic itineraries of patients with ulcerated forms of Mycobacterium ulcerans (Buruli ulcer) disease in a rural health zone in the Democratic Republic of Congo. Trop Med Int Health 2009; 14(9): 1110-1116.
  • Kibadi K, Mputu-Yamba JB, Mokassa B, Panda M, Muyembe-Tamfum JJ. Rechutes après traitement chirurgical exclusif de l'infection à Mycobacterium ulcerans (ulcère de Buruli): étude des facteurs de risque chez 84 patients congolais. Med Trop 2009; 69(5): 471-474.
  • Kibadi K, Muyembe-Tamfum JJ, Ibungu D, Mukanga J, Kayinua E, Minuku JB, Portaels F. Mise en place d'un réseau national de confirmation des cas d'infection à Mycobacterium ulcerans en République Democratique du Congo; phase pilote: zone de santé rurale de Nsona-Mpangu, Province du Bas-Congo. Bull ALLF 2009; 24: 72-74.
  • Lynen L, An S, Koole O, Ros S, De Munter P, Sculier D, Arnould L, Fransen K, Menten J, Boelaert M, Van den Ende J, Colebunders R. An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia. J Acquir Immun Defic Syndr 2009; 52(1): 40-48.
  • Marcotty T, Matthys F, Godfroid J, Rigouts L, Ameni G, van Pittius NG, Kazwala R, Muma J, van Helden P, Walravens K, de Klerk LM, Geoghegan C, Mbotha D, Otte M, Amenu K, Samra NA, Botha C, Ekron M, Jenkins A, Jori F, Kriek N, McCrindle C, Michel A, Morar D, Roger F, Thys E, Van den Bossche P. Zoonotic tuberculosis and brucellosis in Africa: neglected zoonoses or minor public-health issues? The outcomes of a multi-disciplinary workshop. Ann Trop Med Parasitol 2009; 103(5): 401-411.
  • Martin A, Fissette K, Varaine F, Portaels F, Palomino JC. Thin layer agar compared to BACTEC MGIT 960 for early detection of Mycobacterium tuberculosis. J Microbiol Meth 2009; 78(1): 107-108.
  • Martin A, Paasch F, Von Groll A, Fissette K, Almeida P, Varaine F, Portaels F, Palomino JC. Thin-layer agar for detection of resistance to rifampicin, ofloxacin and kanamycin in Mycobacterium tuberculosis isolates. International Journal of Tuberculosis and Lung Disease 2009; 13(10): 1301-1304.
  • Martin A, Waweru PM, Okatch FB, Ouma NA, Bonte L, Varaine F, Portaels F. Implementation of the thin layer agar method for diagnosis of smear-negative pulmonary tuberculosis in a setting with a high prevalence of human immunodeficiency virus infection in Homa Bay, Kenya. J Clin Microbiol 2009; 47(8): 2632-2634.
  • Matthys F, Rigouts L, Sizaire V, Vezhnina N, Lecoq M, Golubeva V, Portaels F, Van der Stuyft P, Kimerling M. Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. PLoS ONE 2009; 4(711): e7954.
  • Matthys F, Van der Stuyft P, Van Deun A. Universal tuberculosis control targets: not so smart [editorial]. Int J Tuberc Lung Dis 2009; 13(8): 923-924.
  • McGann H, Stragier P, Portaels F, Gascoyne-Binzi D, Collyns T, Lucas S, Mawer D. Buruli ulcer in United Kingdom tourist returning from Latin America [dispatch]. Emerging Infectious Diseases 2009; 15(11): 1827-1829.
  • Moens B, López G, Adaui V, González E, Kerremans L, Clark D, Verdonck K, Gotuzzo E, Vanham G, Cassar O, Gessain A, Vandamme AM, Van Dooren S. Development and validation of a multiplex real-time PCR assay for simultaneous genotyping and human T-lymphotropic virus type 1, 2, and 3 proviral load determination. Journal of Clinical Microbiology 2009; 47(11): 3682-3691.
  • Morcillo N, Imperiale B, Palomino JC. New simple decontamination method improves microscopic detection and culture of mycobacteria in clinical practice. Infection Drug Resist 2008; 1: 21-26.
  • Montes M, Sanchez C, Verdonck K, Lake JE, Gonzalez E, Lopez G, Terashima A, Nolan T, Lewis DE, Gotuzzo E, White AC. Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. PLoS Negl Trop Dis 2009; 3(6): 8 pp.
  • Müller B, Hilty M, Berg S, Garcia-Pelayo MC, Dale J, Boschiroli ML, Cadmus S, Ngandolo BNR, Godreuil S, Diguimbaye-Djaibé C, Kazwala R, Bonfoh B, Njanpop-Lafourcade BM, Sahraoui N, Guetarni D, Aseffa A, Mekonnen MH, Razanamparany VR, Ramarokoto H, Djonne B, Oloya J, Machado A, Mucavele C, Skjerve E, Portaels F, Rigouts L, Michel A, Müller A, Källenius G, van Helden PD, Hewinson RG, Zinsstag J, Gordon SV, Smith NH. African 1, an epidemiologically important clonal complex of Mycobacterium bovis dominant in Mali, Nigeria, Cameroon, and Chad. J Bacteriol 2009; 191(6): 1951-1960.
  • Munyeme M, Muma JB, Salui KL, Skjerve E, Nambota AM, Phiri IGK, Rigouts L, Tryland M. Prevalence of bovine tuberculosis and animal level risk factors for indigenous cattle under different grazing strategies in the livestock/wildlife interface areas of Zambia. Trop Anim Health Prod 2009; 41(3): 345-352.
  • Munyeme M, Rigouts L, Shamputa IC, Muma JB, Tryland M, Skjerve E, Djonne B. Isolation and characterization of Mycobacterium bovis strains from indigenous Zambian cattle using Spacer oligonucleotide typing technique. BMC Microbiol 2009; 9(144): 8 pp.
  • Njue C, Voeten HACM, Remes P. Disco funerals: a risk situation for HIV infection among youth in Kisumu, Kenya. AIDS 2009; 23(4): 505-509.
  • Noeske J, Dopico E, Torrea G, Wang H, Van Deun A. Two vs. three sputum samples for microscopic detection of tuberculosis in a high HIV prevalence population. Int J Tuberc Lung Dis 2009; 13(7): 842-847.
  • Ondoa P, Vereecken C, Asahchop EL, Litzroth A, Diallo A, Fransen K, Dieye T, Ryder R, Mboup S, Kestens L. Proof of principle: an HIV p24 microsphere immunoassay with potential application to HIV clinical diagnosis. Cytometry B Clin Cytom 2009; 76(3): 231-236.
  • Palomino JC. Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 2009; 56(2): 103-111.
  • Palomino JC, Ramos DF, da Silva PA. New anti-tuberculosis drugs: strategies, sources and new molecules. Curr Med Chem 2009; 16(15): 1898-1904.
  • Portaels F. L'infection à Mycobacterium ulcerans (ulcère de Buruli): maladie négligée en 2009? Médecine Tropicale 2009; 69(5): 429-430.
  • Portaels F. Obituary: Professor S.R. Pattyn M.D. 1927-2008. Lepr Rev 2009; 80(2): 221-223.
  • Portaels F, Silva MT, Meyers WM. Buruli ulcer. Clin Dermatol 2009; 27(3): 291-305.
  • Proaño-Perez F, Benitez-Ortiz W, Celi-Erazo M, Ron-Garrido L, Benitez-Capistros R, Portaels F, Rigouts L, Linden A. Comparative intradermal tuberculin test in dairy cattle in the north of Ecuador and risk factors associated with bovine tuberculosis. Am J Trop Med Hyg 2009; 81(6): 1103-1109.
  • Ridderhof JC, Van Deun A. Laboratory systems and strategies for tuberculosis. In: Schaaf HS, Zumla AI, editors. Tuberculosis; a comprehensive clinical reference. [s.l.]: Saunders Elsevier, 2009: 738-745.
  • Rigouts L. Clinical practice: diagnosis of childhood tuberculosis. European Journal of Pediatrics 2009; 168(11): 1285-1290.
  • Shikama ML, Ferro e Silva R, Villela G, Sato DN, Martins MC, Giampaglia MS, da Silva RFAM, Ferro e Silva P, da Silva Telles MA, Martin A, Palomino JC. Multicentre study of nitrate reductase assay for rapid detection of rifampicin-resistant M. tuberculosis. Int J Tuberc Lung Dis 2009; 13(3): 377-380.
  • Silva MT, Portaels F, Pedrosa J. Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infectious Diseases 2009; 9(11): 699-710.
  • Sopoh GE, Dossou AD, Johnson RC, Brun LV, Barogui YT, Houezo JG, Affolabi D, Anagonou SY, Asiedu K, Portaels F. Forme multifocale et dissémination des lésions d'ulcère de Buruli après traitement à la streptomycine et rifampicine: à propos d'un cas. Bull ALLF 2009; 24: 75-80.
  • Stragier P. Heterogeneity and molecular characteristics of Mycobacterium ulcerans and related species [dissertation]. Antwerpen: Universiteit Antwerpen, Faculteit Geneeskunde, 2009: 189 pp.
  • Suykerbuyk P, Wambacq J, Phanzu DM, Haruna H, Nakazawa Y, Ooms K, Kamango K, Stragier P, Singa JN, Ekwanzala F, De Herdt E, De Maeyer P, Kestens L, Portaels F. Persistence of Mycobacterium ulcerans disease (Buruli ulcer) in the historical focus of Kasongo territory, the Democratic Republic of Congo. American Journal of Tropical Medicine and Hygiene 2009; 81(5): 888-894.
  • Tebeu PM, de Bernis L, Doh AS, Rochat CH, Delvaux T. Risk factors for obstetric fistula in the Far North Province of Cameroon. International Journal of Gynecology & Obstetrics 2009; 107(1): 12-15.
  • Van den Bergh R. Who is at the receiving end of our innovation? Global Forum for Health Research, Young Voices in Research for Health, 2009.Geneva: Global Forum for Health Research, 2009: 145-147.
  • Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, Rigouts L, Rüsch-Gerdes S, Wright A. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. Journal of Clinical Microbiology 2009; 47(11): 3501-3506.
  • van Ingen J, Boeree MJ, de Lange WCM, de Haas PEW, van der Zanden AGM, Mijs W, Rigouts L, Dekhuijzen PNR, van Soolingen D. Mycobacterium noviomagense sp. nov.; clinical relevance evaluated in 17 patients. Int J Syst Evol Microbiol 2009; 59(4): 845-849.
  • Verdonck K, González E, Maldonado F, Agapito D, Van Dooren S, Vandamme AM, Silva-Santisteban A, Vanham G, Clark D, Gotuzzo E. Comparison of three ELISAs for the routine diagnosis of human T-lymphotropic virus infection in a high-prevalence setting in Peru. Trans R Soc Trop Med Hyg 2009; 103(4): 420-422.
  • Vermeire K, Van Laethem K, Janssens W, Bell TW, Schols D. Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility. Journal of Virology 2009; 83(18): 9577-9583.
  • Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, Almeida da Silva P. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrobial Agents and Chemotherapy 2009; 53(10): 4498-4500.
  • Vuylsteke B, Das A, Dallabetta G, Laga M. Preventing HIV among sex workers. In: HIV prevention; a comprehensive approach. Amsterdam: Elsevier, 2009: 376-406.
  • Walsh DS, Eyase F, Onyango D, Odindo A, Otieno W, Waitumbi JN, Bulimo WD, Schnabel DC, Meyers WM, Portaels F. Clinical and molecular evicence for a case of Buruli Ulcer (Mycobacterium ulcerans infection) in Kenya. Am J Trop Med Hyg 2009; 81(6): 1110-1113.
  • Wright A, Zignol M, Van Deun A, Falzon D, Ruesch Gerdes S, Feldman K, Hoffner S, Drobniewski F, Barrera L, van Soolingen D, Boulabhal F, Paramasivan CN, Kam KM, Mitarai S, Nunn P, Raviglione M. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373(9678): 1861-1873.

2008

  • Affolabi D, Bankolé H, Ablordey A, Hounnouga J, Koutchakpo P, Sopoh G, Aguiar J, Dossou A, Johnson RC, Anagonou S, Portaels F. Effects of grinding surgical tissue specimens and smear staining methods on Buruli ulcer microscopic diagnosis. Trop Med Int Health 2008; 13(2): 187-190.
  • Affolabi D, Odoun M, Sanoussi N, Martin A, Palomino JC, Kestens L, Anagonou S, Portaels F. Rapid and inexpensive detection of multidrug-resistant Mycobacterium tuberculosis with the nitrate reductase assay using liquid medium and direct application to sputum samples. J Clin Microbiol 2008; 46(10): 3243-3245.
  • Affolabi D, Odoun M, Sanoussi CN, Tanimomo-Kledjo B, Saïzonou D, Soumaïla K, Kestens L, Anagonou SY, Portaels F. Bulk staining of smears: no demonstrated risk of bacilli transfer from a positive to a negative smear. Int J Tuberc Lung Dis 2008; 12(6): 683-685.
  • Affolabi D, Sanoussi N, Odoun M, Martin A, Koukpemedji L, Palomino JC, Kestens L, Anagonou S, Portaels F. Rapid detection of multidrug-resistant Mycobacterium tuberculosis in Cotonou (Benin) using two low-cost colorimetric methods: resazurin and nitrate reductase assays. J Med Microbiol 2008; 57(8): 1024-1027.
  • Affolabi D, Tanimomo-Kledjo B, Anyo G, Johnson RC, Anagonou SY, Portaels F. Setting up a national reference laboratory for Buruli ulcer: the case of Benin. Trop Med Int Health 2008; 13(3): 365-368.
  • Beck IA, Crowell C, Kittoe R, Bredell H, Machaba M, Willamson C, Janssens W, Jallow S, van der Groen G, Shao Y, Jacob M, Samuel NM, de Rivera IL, Ngo-Giang-Huong N, Cassol S, Alemnji G, Frenkel LM. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-north American variants. J Acquir Immun Defic Syndr 2008; 48(4): 418-427.
  • Beels D, Heyndrickx L, Vereecken K, Vermoesen T, Michiels L, Vanham G, Kestens L. Production of human immunodeficiency virus type 1 (HIV-1) pseudoviruses using linear HIV-1 envelope expression cassettes. J Virol Methods 2008; 147(1): 99-107.
  • Beels D, Heyndrickx L, Vereecken K, Vermoesen T, Michiels L, Vanham G, Kestens L. Production of human immunodeficiency virus type 1 (HIV-1) pseudoviruses using linear HIV-1 envelope expression cassettes. J Virol Methods 2008; 147(1): 99-107.
  • Bertozzi SM, Laga M, Bautista-Arredondo S, Coutinho A. Making HIV prevention programmes work. Lancet 2008; 372(9641): 831-844.
  • Buvé A, Gourbin C, Laga M. Gender and sexually transmitted diseases; 4th ed. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, Cohen MS, Watts DH, editors. Sexually transmitted diseases. New York: McGraw-Hill, 2008: 151-164.
  • Buvé A, Newell ML. Vulnerability of young women and girls to HIV infection in the hyperendemic countries of southern Africa. AIDS 2008; 22(Suppl.4): 86 pp.
  • Chonde TM, Doulla B, van Leth F, Mfinanga SGM, Range N, Lwilla F, Mfaume SM, Van Deun A, Zignol M, Cobelens FG, Egwaga SM. Implementation of a national anti-tuberculosis drug resistance survey in Tanzania. BMC Public Health 2008; 8(427): 6 pp.
  • Coban AY, Martin A, Uzun M, Bilgin K, Palomino JC, Durupinar B. Evaluation of blood agar for susceptibility testing of Mycobacterium tuberculosis against first-line antituberculous drugs: results from two centers [letter]. J Chemother 2008; 20(3): 388-390.
  • Corbett M, Bogers WM, Heeney JL, Gerber S, Genin C, Didierlaurent A, Oostermeijer H, Dubbes R, Braskamp G, Lerondel S, Gomez CE, Esteban M, Wagner R, Kondova I, Mooij P, Balla-Jhagjhoorsingh S, Beenhakker N, Koopman G, van der Burg S, Kraehenbuhl JP, Le Pape A. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci USA 2008; 105(6): 2046-2051.
  • Crucitti T. The epidemiology of Trichomonas vaginalis; prevalence of Trichomonas sp., and sexual and hygienic risk factors associated with genital trichomoniasis [dissertation]. Antwerpen: Universiteit Antwerpen, Faculteit Farmaceutische, Biomedische en Diergeneeskundige Wetenschappen, Departement Farmaceutische Wetenschappen; Antwerpen: Institute of Tropical Medicine, Department of Microbiology, 2008: 194 pp.
  • Crucitti T, Abdellati S, Van Dyck E, Buvé A. Molecular typing of the actin gene of Trichomonas vaginalis isolates by PCR-restriction fragment length polymorphism. Clin Microbiol Infect 2008; 14(9): 844-852.
  • Delvaux T, Konan JPD, Aké-Tano O, Gohou-Kouassi V, Bosso PE, Buvé A, Ronsmans C. Quality of antenatal and delivery care before and after the implementation of a prevention of mother-to-child HIV transmission programme in C“te d'Ivoire. Trop Med Int Health 2008; 13(8): 970-979.
  • Delvaux T, Soeur S, Rathavy T, Crabbé F, Buvé A. Integration of comprehensive abortion-care services in a maternal and child health clinic in Cambodia. Trop Med Int Health 2008; 13(8): 962-969.
  • Dossou AD, Sopoh GE, Johnson CR, Barogui YT, Affolabi D, Anagonou SY, Zohoun T, Portaels F, Asiedu K. Management of Mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin [letter]. Med J Aust 2008; 189(9): 532-533.
  • Durnez L, Eddyani M, Mgode GF, Katakweba A, Katholi CR, Machang'u RR, Kazwala RR, Portaels F, Leirs H. First detection of mycobacteria in African rodents and insectivores, using stratified pool screening. Appl Environ Microbiol 2008; 74(3): 768-773.
  • Eddyani M, Debacker M, Martin A, Aguiar J, Johnson CR, Uwizeye C, Fisette K, Portaels F. Primary culture of Mycobacterium ulcerans from human tissue specimens after storage in semisolid transport medium. J Clin Microbiol 2008; 46(1): 69-72.
  • Eddyani M, De Jonckheere JF, Durnez L, Suykerbuyk P, Leirs H, Portaels F. Occurrence of free-living amoebae in communities of low and high endemicity for Buruli ulcer in southern Benin. Appl Environ Microbiol 2008; 74(21): 6547-6553.
  • Eyangoh SI, Torrea G, Tejiokem MC, Kamdem Y, Piam FF, Noeske J, Van Deun A. HIV-related incremental yield of bleach sputum concentration and fluorescence technique for the microscopic detection of tuberculosis. Eur J Clin Microbiol Infect Dis 2008; 27(9): 849-855.
  • Familiar O, Munier-Lehmann H, Negri A, Gago F, Douguet D, Rigouts L, Hernández AI, Camarasa MJ, Pérez-Pérez MJ. Exploring acyclic nucleoside analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. ChemMedChem 2008; 3(7): 1083-1093.
  • Gabrysch S, Edwards T, Glynn JR, Study Group on Heterogeneity of HIV Epidemics in African Cities . The role of context: neighbourhood characteristics strongly influence HIV risk in young women in Ndola, Zambia. Trop Med Int Health 2008; 13(2): 162-170.
  • Ganoza CA, Ricaldi JN, Chauca J, Rojas G, Munayco C, Agapito J, Palomino JC, Guerra H. Novel hypertonic saline-sodium hydroxide (HS-SH) method for decontamination and concentration of sputum samples for Mycobacterium tuberculosis microscopy and culture. J Med Microbiol 2008; 57(9): 1094-1098.
  • Guerra H, Palomino JC, Falconí E, Bravo F, Donaires N, Van Marck E, Portaels F. Mycobacterium ulcerans disease, Peru. Emerg Infect Dis 2008; 14(3): 373-377.
  • Gottlieb GS, Eholié SP, Nkengasong JN, Jallow S, Rowland-Jones S, Whittle H, Sow PS. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa [opinion]. AIDS 2008; 22(16): 2069-2072.
  • Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, Oduyebo O, Taylor D, McNeil L, Mehta N, Umo-Otong J, Otusanya S, Crucitti T, Abdellati S. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS ONE 2008; 3(11): e3784.
  • Jallow S. Development and application of assays for monitoring drug resistance in HIV-2 infected patients on antiretroviral therapy [dissertation]. Antwerpen: Universiteit Antwerpen, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, 2008: 175 pp.
  • Jennes W, Camara M, Dièye T, Mboup S, Kestens L. Higher homologous and lower cross-reactive Gag-specific T-cell responses in human immunodeficiency virus type 2 (HIV-2) than in HIV-1 infection. J Virol 2008; 82(17): 8619-8628.
  • Johnson RC, Nackers F, Glynn JR, de Biurrun Bakedano E, Zinsou C, Aguiar J, Tonglet R, Portaels F. Association of HIV infection and [Mycobacterium ulcerans disease in Benin research letter]. AIDS 2008; 22(7): 901-903.
  • Jugheli L, Rigouts L, Shamputa IC, de Rijk WB, Portaels F. High levels of resistance to second-line anti-tuberculosis drugs among prisoners with pulmonary tuberculosis in Georgia. Int J Tuberc Lung Dis 2008; 12(5): 561-566.
  • Kestens L, Seddiki N, Bohjanen PR. Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy. Curr Opin HIV AIDS 2008; 3(4): 419-424.
  • Kibadi K. Infection à Mycobacterium ulcerans traitée par Rifater, Pyrazynamide, Myambutol associés à la chirurgie; à propos d'un cas avec un recul de six ans. Méd Mal Infect 2008; 38(3): 156-158.
  • Kibadi K, Panda M, Muyembe Tamfum JJ, Fraga AG, Filho AL, Anyo G, Pedrosa J, Nakazawa Y, Suykerbuyk P, Meyers WM, Portaels F. New foci of Buruli ulcer, Angola and Democratic Republic of Congo. Emerg Infect Dis 2008; 14(11): 1790-1792.
  • Kibadi K, Stragier P, Muyembe-Tamfum JJ, Pedrosa J, Portaels F. Suivi du premier cas d'infection à Mycobacterium ulcerans confirmé par culture, PCR et génotypage en République du Congo-Brazzaville. Méd Trop 2008; 68(2): 137-143.
  • Laga M, Matendo R, Buvé A. The situation in the cradle of AIDS: Congo and Central Africa. In: Celentano DD, Beyrer C, editors. Public health aspects of HIV/AIDS in low and middle income countries; epidemiology, prevention and care. New York: Springer, 2008: 195-215.
  • Lajoie J, Poudrier J, Massinga-Loembe M, Guédou F, Agossa-Gbenafa C, Labbé AC, Alary M, Roger M. Differences in immunoregulatory cytokine expression patterns in the systemic and genital tract compartments of HIV-1-infected commercial sex workers in Benin. Mucosal Immunology 2008; 1(4): 309-316.
  • López-de Castilla D, Verdonck K, Otero L, Iglesias D, Echevarria J, Lynen L, Gotuzzo E, Seas C. Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru. Int J Infect Dis 2008; 12(3): 325-331.
  • Malaspina AC, Cavalcanti HR, Leite CQF, Machado SMA, Viana BHJ, Silva RMG, Hage EF, Figueiredo WM, Marques E, Ferrazoli L, Arbex M, Lessi M, Fonseca LS, Rigouts L, Saad MHF. Usefulness of Mycobacterium tuberculosis molecular typing in a tuberculosis low-endemic agro-industrial setting of Brazil. Jap J Infect Dis 2008; 61(3): 231-233.
  • Martin A, Cubillos-Ruiz A, Von Groll A, Del Portillo P, Portaels F, Palomino JC. Nitrate reductase assay for the rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother 2008; 61(1): 123-127.
  • Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC, Angeby K. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2008; 62(1): 56-64.
  • Martin A, Von Groll A, Fissette K, Palomino JC, Varaine F, Portaels F. Rapid detection of Mycobacterium tuberculosis resistance to second-line drugs by use of the manual mycobacterium growth indicator tube system. J Clin Microbiol 2008; 46(12): 3952-3956.
  • Nyambi P, Burda S, Urbanski M, Heyndrickx L, Janssens W, Vanham G, Nadas A. Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals. AIDS Res Hum Retroviruses 2008; 24(12): 1507-1519.
  • Padian NS, Buvé A, Balkus J, Serwadda D, Cates W. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008; 372(9638): 585-599.
  • Palomino JC, Martin A. Implementation of rapid colorimetric methods for drug resistance detection in M. tuberculosis: perspectives for low-resource settings. Curr Trends Microbiol 2006; 2: 75-83.
  • Palomino JC, Martin A, Von Groll A, Portaels F. Rapid culture-based methods for drug resistance detection in Mycobacterium tuberculosis. J Microbiol Meth 2008; 75(2): 161-166.
  • Portaels F. L'ulcère de Buruli en Afrique depuis sa découverte jusqu' à nos jours. Bull ALLF 2008; 23: 57-59.
  • Portaels F, Johnson C, Aguiar J, Meyers WM, Debacker M. Etude de 106 cas d'ulcères de Buruli avec atteintes osseuses traités à Zagnanado, Bénin. Bull ALLF 2008; 23: 48-50.
  • Portaels F, Meyers WM, Ablordey A, Castro AG, Chemlal K, de Rijk P, Elsen P, Fissette K, Fraga AG, Lee R, Mahrous E, Small PLC, Stragier P, Torrado E, Van Aerde A, Silva MT, Pedrosa J. First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2008; 2(3): e178.
  • Ritacco V, López B, Cafrune PI, Ferrazoli L, Suffys PN, Candia N, Vásquez L, Realpe T, Fernández J, Lima KV, Zurita J, Robledo J, Rossetti ML, Kritski AL, Telles MA, Palomino JC, Heersma H, van Soolingen D, Kremer K, Barrera L. Mycobacterium tuberculosis strains of Beijing genotype are rarely observed in tuberculosis patients in South America. Mem Inst Oswaldo Cruz 2008; 103(5): 489-492.
  • Ruelle J, Roman F, Vandenbroucke AT, Lambert C, Fransen K, Echahidi F, Piérard D, Verhofstede C, Van Laethem K, Delforge ML, Vaira D, Schmit JC, Goubau P. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis 2008; 8(21): 11 pp.
  • Stevens W, Sherman G, Downing R, Parsons LM, Ou CY, Crowley S, Gershy-Damet GM, Fransen K, Bulterys M, Homsy J, Lu L, Finkbeiner T, Nkengasong JN. Role of the laboratory in ensuring global access to ARV treatment for HIV-infected children: consensus statement on the performance of laboratory assays for early infant diagnosis. Open AIDS J 2008; 2: 17-25.
  • Stragier P, Hermans K, Stinear T, Portaels F. First report of a mycolactone-producing Mycobacterium infection in fish agriculture in Belgium [research letter]. FEMS Microbiol Lett 2008; 286(1): 93-95.
  • Terrazas-Aranda K, Van Herrewege Y, Hazuda D, Lewi P, Costi R, Di Santo R, Cara A, Vanham G. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob Agents Chemother 2008; 52(7): 2544-2554.
  • Torrea G, Chakaya J, Mayabi M, Van Deun A. Evaluation of the FluoreslenS(TM) and fluorescence microscopy blinded rechecking trial, Nairobi, Kenya. Int J Tuberc Lung Dis 2008; 12(6): 658-663.
  • Umubyeyi A, Rigouts L, Shamputa IC, Dediste A, Struelens M, Portaels F. Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda. Int J Infect Dis 2008; 12(2): 152-156.
  • Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359(5): 463-472.
  • Van Deun A. Optimization of smear microscopy for acid-fast bacilli in tuberculosis control programs [dissertation]. Leuven: Leuven University Press, 2008: 201 pp. (Acta Biomedica Lovaniensia).
  • Van Deun A, Chonde TM, Gumusboga M, Rienthong S. Performance and acceptability of the FluoLED Easy (TM) module for tuberculosis fluorescence microscopy. Int J Tuberc Lung Dis 2008; 12(9): 1009-1014.
  • Van Deun A, Chuquiyauri R, Torrea G, Agapito J, Verdonck K, Gotuzzo E. Yield of fluorescence microscopy versus culture for tuberculosis at a middle-income country referral hospital. Trans R Soc Trop Med Hyg 2008; 102(6): 564-569.
  • Van Deun A, Hossain MA, Gumusboga M, Rieder HL. Ziehl-neelsen staining: theory and practice. Int J Tuberc Lung Dis 2008; 12(1): 108-110.
  • Van Gulck E. Dendritic cells loaded with gag mRNA from HIV quasispecies for the development of a cellular therapeutic va [dissertation]. Antwerpen: Universiteit Antwerpen, Faculteit Farmaceutische, Biomedische en Diergeneeskundige Wetenschappen, Biomedische Wetenschappen, 2008: 205 pp.
  • Van Gulck ER, Vanham G, Heyndrickx L, Coppens S, Vereecken K, Atkinson D, Florence E, Kint I, Berneman ZN, Van Tendeloo V. Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific t-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals. J Virol 2008; 82(7): 3561-3573.
  • Van Herrewege Y, Morellato L, Descours A, Aerts L, Michiels J, Heyndrickx L, Martin L, Vanham G. CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. J Antimicrob Chemother 2008; 61(4): 818-826.
  • Van Rie A, Fitzgerald D, Kabuya G, Van Deun A, Tabala M, Jarret N, Behets F, Bahati E. Sputum smear microscopy: evaluation of impact of training, microscope distribution, and use of external quality assessment guidelines for resource-poor settings. J Clin Microbiol 2008; 46(3): 897-901.
  • Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Deforche K, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Van den Heuvel A, Van der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Vandamme AM, Van Laethem K. Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 2008; 24(3): 355-362.
  • Verdonck K. Clinical aspects and epidemiology of human T-lymphotropic virus 1 infection in Peru [dissertation]. Antwerpen: Universiteit Antwerpen, Faculteit Geneeskunde, 2008: 181 pp.
  • Verdonck K, González E, Schrooten W, Vanham G, Gotuzzo E. HTLV-1 infection is associated with a history of active tuberculosis among family members of HTLV-1-infected patients in Peru. Epidemiol Infect 2008; 136(8): 1076-1083.
  • Vermeire K, Brouwers J, Van Herrewege Y, Le Grand R, Vanham G, Augustijns P, Bell TW, Schols D. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Curr HIV Res 2008; 6(3): 246-256.
  • Vuylsteke B, Laga M. Approach to management of STIs in developing countries; 4th ed. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, Cohen MS, Watts DH, editors. Sexually transmitted diseases. New York: McGraw-Hill, 2008: 1993-2012.
  • Walsh DS, Portaels F, Meyers WM. Buruli ulcer (Mycobacterium ulcerans infection). Trans R Soc Trop Med Hyg 2008; 102(10): 969-978.
  • White RG, Freeman EE, Orroth KK, Bakker R, Weiss HA, O'Farrell N, Buvé A, Hayes RJ, Glynn JR. Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa. Sex Transm Infect 2008; 84(Suppl.2): ii12-ii18.
  • White RG, Glynn JR, Orroth KK, Freeman EE, Bakker R, Weiss HA, Kumaranayake L, Habbema JDF, Buvé A, Hayes RJ. Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when? AIDS 2008; 22(14): 1841-1850.
  • White RG, Orroth KK, Glynn JR, Freeman EE, Bakker R, Habbema JDF, Terris-Prestholt F, Kumaranayake L, Buvé A, Hayes RJ. Treating curable sexually transmitted infections to prevent HIV in Africa; still an effective control strategy? J Acquir Immun Defic Syndr 2008; 47(3): 346-353.
 

2007

  • Ablordey A. Development of molecular methods for the study of genetic diversity in Mycobacterium ulcerans [dissertation]. Ghent: University of Ghent, Laboratory of Microbiology; Antwerp: Institute of Tropical Medicine, Department of Microbiology, Mycobacteriology Unit, 2007: 130 pp.
  • Ablordey A, Fonteyne PA, Stragier P, Vandamme P, Portaels F. Identification of a new variable number tandem repeat locus in Mycobacterium ulcerans for potential strains discrimination among African isolates. Clin Microbiol Infect 2007; 13(7): 734-736.
  • Adu-Sarkodie Y, Opoku BK, Crucitti T, Weiss HA, Mabey D. Lack of evidence for the involvement of rectal and oral trichomonads in the aetiology of vaginal trichomoniasis in Ghana. Sex Transm Infect 2007; 83(2): 130-132.
  • Affolabi D, Adjagba OABG, Tanimomo-Kledjo B, Gninafon M, Anagonou SY, Portaels F. Anti-tuberculosis drug resistance among new and previously treated pulmonary tuberculosis patients in Cotonou, Benin. Int J Tuberc Lung Dis 2007; 11(11): 1221-1224.
  • Affolabi D, Odoun M, Martin A, Palomino JC, Anagonou S, Portaels F. Evaluation of direct detection of Mycobacterium tuberculosis rifampin resistance by a nitrate reductase assay applied to sputum samples in Cotonou, Benin. J Clin Microbiol 2007;45(7): 2123-2125.
  • Ariën KK, Vanham G, Arts EJ. Is HIV-1 evolving to a less virulent horm in humans? [opinion]. Nature Rev Microbiol 2007; 5(2): 141-151.
  • Balzarini J, Van Herrewege Y, Vermeire K, Vanham G, Schols D. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol 2007; 71(1): 3-11.
  • Bloom DE, Buvé A. Business and AIDS in South Africa [editorial]. AIDS 2007; 21(Suppl.1): S1.
  • Buvé A, Delvaux T, Criel B. Delivery of male circumcision services: "Festina lente". Reprod Health Matt 2007; 15(29): 57-61.
  • Buvé A. Should all pregnant women be screened for syphilis? Women's Health 2007; 3(4): 547-555.
  • Cabada MM, Maldonado F, Bauer I, Verdonck K, Seas C, Gotuzzo E. Sexual behavior, knowledge of STI prevention, and prevalence of serum markers for STI among tour guides in Cuzco/Peru. J Travel Med 2007; 14(3): 151-157.
  • Chauca JA, Palomino JC, Guerra H. Evaluation of the accuracy of the microplate Alamar Blue assay for rapid detection of MDR-TB in Peru. Int J Tuberc Lung Dis 2007; 11(7): 820-822.
  • Chauca JA, Palomino JC, Guerra H. Evaluation of rifampicin and isoniazid susceptibility testing of Mycobacterium tuberculosis by a mycobacteriophage D29-based assay. J Med Microbiol 2007; 56(3): 360-364.
  • Chuwuekezie O, Ampadu E, Sopoh G, Dossou A, Tiendregeogo A, Sadiq L, Portaels F, Asiedu K. Buruli ulcer, Nigeria [letter]. Emerg Infect Dis 2007; 13(5): 783-784.
  • Crucitti T, Vandenbruaene M. STIs: diagnostic and clinical implications of recent epidemiology. In: Diagnose en surveillance van infectieuse aandoeningen; 23ste seminarie van het Wetenschappelijk Instituut Volksgezondheid, 22/11/2007. [s.l.]: [s.n.], 2007: 15-21.
  • Crucitti T, Jespers V, Van Damme L, Van Dyck E, Buvé A. Vaginal microbicides can interfere with nucleic acid amplification tests used for the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae infection. Diagn Microbiol Infect Dis 2007; 57(1): 97-99.
  • Delvaux T, Nöstlinger C. Reproductive choice for women and men living with HIV: contraception, abortion and fertility. Reprod Health Matt 2007; 15(29(Suppl.)): 46-66.
  • Delvaux T, Aké-Tano O, Gohou-Kouassi V, Bosso P, Simon C, Ronsmans C. Quality of normal delivery care in Côte d'ivoire. Afr J Reprod Health 2007; 11(1): 22-32.
  • Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007; 81(12): 6548-6562.
  • Eddyani M, Portaels F. Survival of Mycobacterium ulcerans at 37°C. Clin Microbiol Infect 2007; 13(10): 1033-1035.
  • Freeman EE, Orroth KK, White RG, Glynn JR, Bakker R, Boily MC, Habbema D, Buvé A, Hayes RJ. Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Transm Infect 2007; 83(Suppl.1): i17-i24.
  • Gali Y, Berkhout B, Vanham G, Bakker M, Back NKT, Ariën KK. Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam cohort. Virology 2007; 364(1): 140-146.
  • Gilpin C, Kim SJ, Lumb R, Rieder HL, Van Deun A. Critical appraisal of current recommendations and practices for tuberculosis sputum smear microscopy [workshop report]. Int J Tuberc Lung Dis 2007; 11(9): 946-952.
  • Gotuzzo E, Moody J, Verdonck K, Cabada MM, González E, Van Dooren S, Vandamme AM, Terashima A, Vermund SH. Frequent HTLV-1 infection in the offspring of Peruvian women with HTLV-1-associated myelopathy/tropical spastic paraparesis or strongyloidiasis. Rev Panam Salud Pública 2007; 22(4): 223-230.
  • Huyst V, Lynen L, Bottieau E, Zolfo M, Kestens L, Colebunders R. Immune reconstitution inflammatory syndrome in an HIV/TB co-infected patient four years after starting antiretroviral therapy. Acta Clin Belg 2007; 62(2): 126-129.
  • Jallow S, Kaye S, Schutten M, Brandin E, Albert J, McConkey SJ, Corrah T, Whittle H, Vanham G, Rowland-Jones S, Janssens W. Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene. J Clin Microbiol 2007; 45(5): 1565-1571.
  • Jespers V, Buvé A, Van Damme L. Safety trial of the vaginal microbicide cellulose sulfate gel in HIV-positive men. Sex Transm Dis 2007; 34(7): 519-522.
  • Jespers V, Laga M, Van Herrewege Y, Vanham G. Microbicides: a long and bumpy road to success? AIDS Rev 2007; 9(1): 61-62.
  • Jespers VA, Van Roey JM, Beets GI, Buvé AM. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immun Defic Syndr 2007; 44(2): 154-158.
  • Kabedi MJ, Kashongwe M, Kayembe JM, Mumba Ngoyi D, Mampasi P, Mbaya P, Fissette K, Verhaegen J, Portaels F, Muyembe-Tamfum JJ. Résistance primaire de Mycobacterium tuberculosis aux anti-tuberculeux … Kinshasa, République Démocratique du Congo. Bull Soc Pathol Exot 2007; 100(4): 275-276.
  • Käser M, Rondini S, Naegeli M, Stinear T, Portaels F, Certa U, Pluschke G. Evolution of two distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans [electronic only]. BMC Evol Biol 2007; 7(177): 14 pp.
  • Kibadi K, Aujoulat I, Meyers WM, Mokassa L, Muyembe T, Portaels F. Etude des appellations et des représentations attachées à l'infection à Mycobacterium ulcerans dans différents pays endémiques d'Afrique. Méd Trop 2007; 67(3): 241-248.
  • Kibadi K, Nkuku L, Singa J, Mputu-Yamba JB, Mokassa L, Muyembe TJJ, Portaels F. Phénomène 'mbasu' ou ulcère de Buruli à Kinshasa: mythe ou réalité! Résultats préliminaires. Congo Méd 2007; 4(11): 1000-1005.
  • Martin A, Portaels F, Palomino JC. Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 59(2): 175-183.
  • Nackers F, Johnson RC, Glynn JR, Zinsou C, Tonglet R, Portaels F. Environmental and health-related risk factors for Mycobacterium ulcerans disease (Buruli ulcer) in Benin. Am J Trop Med Hyg 2007; 77(5): 834-836.
  • Nackers F, Tonglet R, Slachmuylder V, Johnson RC, Robert A, Zinsou C, Glynn JR, Portaels F, Gala JL. Association between haemoglobin variants S and C and Mycobacterium ulcerans disease (Buruli ulcer): a case-control study in Benin. Trop Med Int Health 2007; 12(4): 511-518.
  • Palomino JC, Leao SC, Ritacco V, editors. Tuberculosis 2007; from basic science to patient care [electronic only]. [s.l.]: [s.n.], 2007: 687 pp.
  • Palomino JC, Martin A, Portaels F. MODS assay for the diagnosis of TB [letter]. N Engl J Med 2007; 356(2): 188.
  • Palomino JC, Martin A, Portaels F. Rapid drug resistance detection in Mycobacterium tuberculosis: a review of colourimetric methods. Clin Microbiol Infect 2007; 13(8): 754-762.
  • Pouillot R, Matias G, Mbondji Wondje C, Portaels F, Valin N, Ngos F, Njikap A, Marsollier L, Fontanet A, Eyangoh S. Risk factors for Buruli ulcer: a case control study in Cameroon. PLoS Negl Trop Dis 2007; 1(3): e101.
  • Quezada CM, Kamanzi E, Mukamutara J, de Rijk P, Rigouts L, Portaels F, Ben Amor Y. Implementation validation performed in Rwanda to determine whether the INNO-LiPA rif.TB line probe assay can be used for detection of multidrug-resistant Mycobacterium tuberculosis in low-resource countries. J Clin Microbiol 2007; 45(9): 3111-3114.
  • Rahim Z, Zaman K, van der Zanden AGM, Möllers MJ, van Soolingen D, Raqib R, Zaman K, Begum V, Rigouts L, Portaels F, Rastogi N, Sola C. Assessment of population structure and major circulating phylogeographical clades of Mycobacterium tuberculosis complex in Bangladesh suggests a high prevalence of a specific subclade of ancient M. tuberculosis genotypes. J Clin Microbiol 2007; 45(11): 3791-3794.
  • Rigouts L, Nolasco O, de Rijk P, Nduwamahoro E, Van Deun A, Ramsay A, Arevalo J, Portaels F. Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol 2007; 45(1): 252-254.
  • Rivoire N, Ravololonandriana P, Rasolonavalona T, Martin A, Portaels F, Ramarokoto H, Razanamparany VR. Evaluation of the resazurin assay for the detection of multidrug-resistant Mycobacterium tuberculosis in Madagascar. Int J Tuberc Lung Dis 2007; 11(6): 683-688.
  • Rondini S, Käser M, Stinear T, Tessier M, Mangold C, Dernick G, Naegeli M, Portaels F, Certa U, Pluschke G. Ongoing genome reduction in Mycobacterium ulcerans. Emerg Infect Dis 2007; 13(7): 1008-1015.
  • Savage EJ, Ison CA, van de Laar MJW, ESSTI Network. Results of a Europe-wide investigation to assess the presence of a new variant of Chlamydia trachomatis [electronic only]. Eurosurveillance Monthly 2007; 12(10).
  • Shamputa IC, Van Deun A, Salim MAH, Hossain MA, Fissette K, de Rijk P, Rigouts L, Portaels F. Endogenous reactivation and true treatment failure as causes of recurrent tuberculosis in a high incidence setting with a low HIV infection. Trop Med Int Health 2007; 12(6): 700-708.
  • Siddiqi K, Newell JN, Van der Stuyft P, Gotuzzo E, Torrico F, Van Deun A, Walley J. Improving sputum microscopy services for the diagnosis of tuberculosis in Peru and Bolivia. Int J Tuberc Lung Dis 2007; 11(6): 665-670.
  • Silva MT, Portaels F, Pedrosa J. Aquatic insects and Mycobacterium ulcerans: an association relevant to Buruli ulcer control? [electronic only]. PLoS Med 2007; 4(2): 229-231 [e63].
  • Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, Drobniewski F, Gilpin C, Havelková M, Lepe R, Lumb R, Metchock B, Portaels F, Rodrigues MF, Rüsch-Gerdes S, Van Deun A, Vincent V, Laserson K, Wells C, Cegielski JP. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13(3): 380-387.
  • Sopoh GE, Johnson RC, Chauty A, Dossou AD, Aguiar J, Salmon O, Portaels F, Asiedu K. Buruli ulcer surveillance, Benin, 2003-2005. Emerg Infect Dis 2007; 13(9): 1374-1376.
  • Steyaert S, Heyndrickx L, Verhoye L, Vermoesen T, Donners H, Fransen K, Van Wanzeele F, Vandergucht B, Vanham G, Leroux-Roels G, Vanlandschoot P. Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients. Antiviral Research 2007; 75(2): 129-138.
  • Steyaert S, Verhoye L, Beirnaert E, Donners H, Fransen K, Heyndrickx L, Vanham G, Leroux-Roels G, Vanlandschoot P. The intraspleen huPBL NOD/SCID model to study the human HIV-specific antibody response selected in the course of natural infection. J Immunol Methods 2007; 320(1-2): 49-57.
  • Suykerbuyk P, Vleminckx K, Pasmans F, Stragier P, Ablordey A, Tran HT, Hermans K, Fleetwood M, Meyers WM, Portaels F. Mycobacterium liflandii infection in European colony of Silurana tropicalis. Emerg Infect Dis 2007; 13(5): 743-746.
  • Terrazas-Aranda K, Van Herrewege Y, Lewi PJ, Van Roey J, Vanham G. In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection. Antivir Chem Chemother 2007; 18(3): 141-151.
  • Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, Portaels F, Silva MT, Pedrosa J. Evidence for intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 2007; 75(2): 977-987.
  • Umubyeyi AN. Apport de la microbiologie dans la prise en charge thérapeutique de la tuberculose au Rwanda [dissertation]. Bruxelles: Université Libre de Bruxelles (ULB), Faculté de Médecine, 2007: 185 pp.
  • Umubyeyi A, Struelens M, Portaels F. Implementation in low-income countries of colorimetric methods as novel rapid antimicrobial susceptibility tests for Mycobacterium tuberculosis. Rwanda Med J 2007; 66(2): 12-21.
  • Umubyeyi AN, Rigouts L, Shamputa IC, Fissette K, Elkrim Y, de Rijk PWB, Struelens MJ, Portaels F. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Chemother 2007; 59(5): 1031-1033.
  • Umubyeyi AN, Rigouts L, Zissis G, Kamanzi E, Pauwels P, Gasana M, Vandebriel G, Struelens M, Portaels F. Résistance primaire et acquise aux antituberculeux des souches de Mycobacterium tuberculosis isolées au Rwanda. Méd Trop 2007; 67(2): 149-153.
  • Umubyeyi AN, Shamputa IC, Rigouts L, Dediste A, Karita E, Struelens MJ, Portaels F. Molecular investigation of recurrent tuberculosis in patients from Rwanda. Int J Tuberc Lung Dis 2007; 11(8): 860-867.
  • Umubyeyi A, Shamputa IC, Rigouts L, Dediste A, Struelens M, Portaels F. Evidence of 'amplifier effect' in pulmonary multidrug-resistant tuberculosis: report of three cases. Int J Infect Dis 2007; 11(6): 508-512.
  • Umubyeyi AN, Vandebriel G, Gasana M, Basinga P, Zawadi JP, Gatabazi J, Pauwels P, Nzabintwali F, Nyiramasarabwe L, Fissette K, Rigouts L, Struelens MJ, Portaels F. Results on a national survey on drug resistance among pulmonary tuberculosis patients in Rwanda. Int J Tuberc Lung Dis 2007; 11(2): 189-194.
  • Van Deun A, Zwahlen M, Bola V, Lebeke R, Bahati E, Lubamba P, Rieder HL. Validation of candidate smear microscope quality indicators, extracted from tuberculosis laboratory registers. Int J Tuberc Lung Dis 2007; 11(3): 300-305.
  • Van Herrewege Y, Michiels J, Waeytens A, De Boeck G, Salden E, Heyndrickx L, van den Mooter G, de Béthune MP, Andries K, Lewi P, Praet M, Vanham G. A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides. Antiviral Research 2007; 74(2): 111-124.
  • Vandepitte JM, Malele F, Kivuvu DM, Edidi S, Muwonga J, Lepira F, Abdellati S, Kabamba J, Van Overloop C, Buvé A. HIV and other sexually transmitted infections among female sex workers in Kinshasa, Democratic Republic of Congo, in 2002. Sex Transm Dis 2007; 34(4): 203-208.
  • Vansnick E, de Rijk P, Vercammen F, Rigouts L, Portaels F, Geysen D. A DNA sequence capture extraction method for detection of Mycobacterium avium subspecies paratuberculosis in feces and tissue samples. Vet Microbiol 2007; 122(1-2): 166-171.
  • Verdonck K, González E, Henostroza G, Nabeta P, Llanos F, Cornejo H, Vanham G, Seas C, Gotuzzo E. HTLV-1 infection is frequent among out-patients with pulmonary tuberculosis in northern Lima, Peru. Int J Tuberc Lung Dis 2007; 11(10): 1066-1072.
  • Verdonck K, González E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7(4): 266-281.
  • Vereecken K, Naus CWA, Polman K, Scott JT, Diop M, Gryseels B, Kestens L. Associations between specific antibody responses and resistance to reinfection in a Senegalese population recently exposed to Schistosoma mansoni. Trop Med Int Health 2007; 12(3): 431-444.
  • Walsh DS, de la Cruz EC, Abalos RM, Tan EV, Walsh GP, Portaels F, Meyers WM. Clinical and histologic features of skin lesions in a cynomolgus monkey experimentally infected with Mycobacterium ulcerans (Buruli ulcer) by intradermal inoculation. Am J Trop Med Hyg 2007; 76(1): 132-134.
  • Yip MJ, Porter JL, Fyfe JAM, Lavender CJ, Portaels F, Rhodes M, Kator H, Colorni A, Jenkin GA, Stinear T. Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor. J Bacteriol 2007; 189(5): 2021-2029.
  • Yzquierdo SL, Lemus D, Echemendia M, Montoro E, McNerney R, Martin A, Palomino JC. Evaluation of phage assay for rapid phenotypic detection of rifampicin resistance in Mycobacterium tuberculosis. Ann Clin Microbiol Antimicrob 2006; 5(11): 5 pp. 2007
 

2006

  • Abdel Aziz M, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, Wells C, Nunn P, Blanc L, Raviglione M. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006; 368(9553): 2142-2154.
  • Adaui V, Verdonck K, Best I, Gonzalez E, Tipismana M, Arévalo J, Vanham G, Campos M, Zimic M, Gotuzzo E. SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers; influence of clinical status, sex, and familial relatedness. J Neurovirol 2006; 12(6): 456-465.
  • Ariën KK, Gali Y, El-Abdellati A, Heyndrickx L, Janssens W, Vanham G. Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones. Virology 2006; 347(1): 65-74.
  • Best I, Adaui V, Verdonck K, González E, Tipismana M, Clark D, Gotuzzo E, Vanham G. Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru. Clin Exp Immunol 2006; 143(2): 226-233.
  • Brudey K, Driscoll JR, Rigouts L, [...], Portaels F. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 2006; 6(23): 17 pp.
  • Buvé A. L'épidémie de VIH en Afrique subsaharienne, pourquoi si grave, pourquoi si hétérogène? In: Denis P, Becker C, editors. L'épidémie du SIDA en Afrique subsaharienne; regards historiens. Louvain-la-Neuve: Academia-Bruylant, 2006: 63-90. (Collection Espace Afrique; 6).
  • Buvé A. Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis [commentary]. Sex Transm Infect 2006; 82(2): 110.
  • Cham F, Zhang PF, Heyndrickx L, Bouma P, Zhong P, Katinger H, Robinson J, van der Groen G, Quinnan GV. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity. Virology 2006; 347(1): 36-51.
  • Davis D, Donners H, Willems B, Ntemgwa M, Vermoesen T, van der Groen G, Janssens W. Neutralization kinetics of sensitive and resistant subtype B primary human immunodeficiency virus type 1 isolates. J Med Virol 2006; 78(7): 864-876.
  • Debacker M, Portaels F, Aguiar J, Steunou C, Zinsou C, Meyers W, Dramaix M. Risk factors for Buruli ulcer, Benin. Emerg Infect Dis 2006; 12(9): 1325-1331.
  • Duker AA, Portaels F, Hale M. Pathways of Mycobacterium ulcerans infection: a review. Environ Int 2006; 32(4): 567-573.
  • Echevarria J, López de Castilla D, Seas C, Verdonck K, Gotuzzo E. Scaling-up highly active antiretroviral therapy (HAART) in Peru: problems on the horizon [letter]. J Acquir Immun Defic Syndr 2006; 43(5): 625-626.
  • García Ribas S, Heyndrickx L, Ondoa P, Fransen K. Performance evaluation of the two protease sequencing primers of the Trugene HIV-1 genotyping kit. J Virol Methods 2006; 135(2): 137-142.
  • Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368(9541): 1106-1118.
  • Hamid Salim A, Aung KJM, Hossain MA, Van Deun A. Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB. Int J Tuberc Lung Dis 2006; 10(11): 1248-1254.
  • Heeney JL, Rutjens E, Verschoor EJ, Niphuis H, ten Haaft P, Rouse S, McClure H, Balla-Jhagjhoorsingh S, Bogers W, Salas M, Cobb K, Kestens L, Davis D, van der Groen G, Courgnaud V, Peeters M, Murthy KK. Transmission of simian immunodeficiency virus SIVcpz and the evolution of infection in the presence and absence of concurrent human immunodeficency virus type 1 infection in chimpanzees. J Virol 2006; 80(14): 7208-7218.
  • Hilty M, Yeboah-Manu D, Boakye D, Mensah-Quainoo E, Rondini S, Schelling E, Ofori-Adjei D, Portaels F, Zinsstag J, Pluschke G. Genetic diversity in Mycobacterium ulcerans isolates from Ghana revealed by a newly identified locus containing a variable number of tandem repeats. J Bacteriol 2006; 188(4): 1462-1465.
  • Jallow S, Kaye S, Alabi A, Aveika A, Sarge-Njie R, Sabally S, Corrah T, Whittle H, Vanham G, Rowland-Jones S, Janssens W, McConkey SJ. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia [research letter]. AIDS 2006; 20(10): 1455-1458.
  • Jennes W. Alloimmune responses and resistance against HIV infection [interview]. Mod Asp Immunobiol 2006; 19: 18.
  • Jennes W, Evertse D, Borget MY, Vuylsteke B, Maurice C, Nkengasong JN, Kestens L. Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers. Clin Exp Immunol 2006; 143(3): 435-444.
  • Jennes W, Verheyden S, Demanet C, Adjé-Touré CA, Vuylsteke B, Nkengasong JN, Kestens L. Resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 2006; 177(10): 6588-6592.
  • Kibadi AK. Les rechutes après traitement de l'ulcère de Buruli par la chirurgie en Afrique. Bull Soc Pathol Exot 2006; 99(4): 230-235.
  • Kibadi KA, Singa NJ, Wembanyama H, Portaels F. Résultats de l'enquête nationale préliminaire sur l'ulcère de Buruli en République Démocratique du Congo. Bull ALLF 2006; 18: 24-26.
  • Kiszewski AE, Becerril E, Aguilar LD, Kader ITA, Meyers W, Portaels F, Hernàndez Pando R. The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol 2006; 143(3): 445-451.
  • Lemus D, Montoro E, Echemendia M, Martin A, Portaels F, Palomino JC. Nitrate reductase assay for detection of drug resistance in Mycobacterium tuberculosis: simple and inexpensive method for low-resource laboratories. J Med Microbiol 2006; 55(7): 861-863.
  • Lynen L, Teav S, Vereecken C, De Munter P, An S, Jacques G, Kestens L. Validation of primary CD4 gating as an affordable strategy for absolute CD4 counting in Cambodia. J Acquir Immun Defic Syndr 2006; 43(2): 179-185.
  • Martin A. Rapid and inexpensive tools for the detection of drug resistance in tuberculosis: applicability in the field [dissertation]. Gent: Universiteit Gent, Vakgroep Biochemie, Fysiologie en Microbiologie; Antwerp: Institute of Tropical Medicine, 2006: 141 pp.
  • Martin A, Takiff H, Vandamme P, Swings J, Palomino JC, Portaels F. A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother 2006; 58(2): 327-331.
  • Meyers WM, Portaels F. Mycobacterium ulcerans infection (Buruli ulcer); 2nd ed. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases; principles, pathogens, & practice. Philadelphia: Elsevier/Churchill Livingstone, 2006: 428-435.
  • Nateche F, Martin A, Baraka S, Palomino JC, Khaled S, Portaels F. Application of the resazurin microtitre assay for detection of multidrug resistance in Mycobacterium tuberculosis in Algiers. J Med Microbiol 2006; 55(7): 857-860.
  • Njai HF, Gali Y, Vanham G, Clybergh C, Jennes W, Vidal N, Butel C, Mpoudi-Ngolle E, Peeters M, Ariën KK. The predominance of human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness. Retrovirology 2006; 3(40): 11 pp.
  • Odaibo GN, Olaleye DO, Heyndrickx L, Vereecken K, Houwer K, Janssens W. Mother-to-child transmission of different HIV-1 subtypes among ARV naive infected pregnant women in Nigeria. Rev Inst Med Trop S Paulo 2006; 48(2): 77-80.
  • Ondoa P, Dieye TN, Vereecken C, Camara M, Diallo AA, Fransen K, Litzroth A, Mboup S, Kestens L. Evaluation of HIV-1 p24 antigenemia and level of CD8+CD38+ T cells as surrogate markers of HIV-1 RNA viral load in HIV-1-infected patients in Dakar. J Acquir Immun Defic Syndr 2006; 41(4): 416-424.
  • Osores F, Nolasco O, Verdonck K, Arévalo J, Ferrufino JC, Agapito J, Huayanay L, Gotuzzo E, Maguiña C. Clinical evaluation of a 16S ribosomal RNA polymerase chain reaction test for the diagnosis of lymph node tuberculosis. Clin Infect Dis 2006; 43(7): 855-859.
  • Palomino JC, Martin A. Implementation of rapid colorimetric methods for drug resistance detection in M. tuberculosis: perspectives for low-resource settings. Curr Trends Microbiol 2006; 2: 75-83.
  • Palomino JC. Newer diagnostics for tuberculosis and multi-drug resistant tuberculosis. Curr Opin Pulm Med 2006; 12(3): 172-178.
  • Phanzu DM, Bafende EA, Dunda BK, Imposo DB, Kibadi AK, Nsiangana SZ, Singa JN, Meyers WM, Suykerbuyk P, Portaels F. Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002-2004. Am J Trop Med Hyg 2006; 75(2): 311-314.
  • Portaels F, Meyers WM. Buruli ulcer. In: Faber WR, Hay RJ, Naafs B, editors. Imported skin diseases. Maarssen: Elsevier Gezondheidszorg, 2006: 117-129.
  • Portaels F, Rigouts L, Shamputa IC, Van Deun A, Abdel Aziz M. Tuberculosis drug resistance in the world; 3rd ed. In: Raviglione MC, editor. Reichman and Hershfield's tuberculosis; a comprehensive, international approach. New York: Informa Healthcare USA, 2006: 823-843. (Lenfant C, editor. Lung Biology in Health and Disease; 219). Proaño-Pérez F, Rigouts L, Brandt J, Dorny P, Ron J, Chavez MA, Rodríguez R, Fissette K, Van Aerde A, Portaels F, Benítez-Ortiz W. Preliminary observations on Mycobacterium spp. in dairy cattle in Ecuador. Am J Trop Med Hyg 2006; 75(2): 318-323.
  • Robledo JA, Mejia GI, Morcillo N, Chacón L, Camacho M, Luna J, Zurita J, Bodon A, Velasco M, Palomino JC, Martin A, Portaels F. Evaluation of a rapid culture method for tuberculosis diagnosis; a Latin American multi-center study. Int J Tuberc Lung Dis 2006; 10(6): 613-619.
  • Ross DA, Wight D, Dowsett G, Buvé A, Obasi AIN. The weight of evidence: a method for assessing the strength of evidence on the effectiveness of HIV prevention interventions among young people. In: Ross DA, Dick B, Ferguson J, editors. Preventing HIV/AIDS in young people; a systematic review of the evidence from developing countries. Geneva: World Health Organization (WHO), 2006: 79-102. (WHO Technical Report Series; 938).
  • Sajduda A, Dziadek J, Kotlowski R, Portaels F. Evaluation of multiple genetic markers for typing drug-resistant Mycobacterium tuberculosis strains from Poland. Diagn Microbiol Infect Dis 2006; 55(1): 59-64.
  • Sanders M, Van Deun A, Ntakirutimana D, Masabo JP, Rukundo J, Rigouts L, Fissette K, Portaels F. Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi; results of a drug resistance survey. Int J Tuberc Lung Dis 2006; 10(2): 178-183.
  • Shamputa IC. Molecular epidemiology of tuberculosis focusing on heterogeneity and mixed infection [dissertation]. Brussel: Vrije Universiteit Brussel, Faculteit Geneeskunde en Farmacie; Antwerp: Institute of Tropical Medicine, 2006: 138 pp.
  • Shamputa IC, Jugheli L, Sadradze N, Willery E, Portaels F, Supply P, Rigouts L. Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia [electronic only]. Resp Res 2006; 7(99): 10 pp.
  • Sizaire V, Nackers F, Comte E, Portaels F. Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect Dis 2006; 6(5): 288-296.
  • Stragier P, Ablordey A, Bayonne LM, Lugor YL, Sindani IS, Suykerbuyk P, Wabinga H, Meyers WM, Portaels F. Heterogeneity among Mycobacterium ulcerans isolates from Africa. Emerg Infect Dis 2006; 12(5): 844-847.
  • Tavernier A, Jennes W, Fransen K, De Roo A, Kestens L. Dominant ex vivo cross-stimulation of CD8+ T-cells with whole soluble Gag protein in HIV-infected subjects. J Acquir Immun Defic Syndr 2006; 41(5): 548-556.
  • Traore H, Van Deun A, Shamputa IC, Rigouts L, Portaels F. Direct detection of Mycobacterium tuberculosis complex DNA and rifampin resistance in clinical specimens from tuberculosis patients by line probe assay. J Clin Microbiol 2006; 44(12): 4384-4388.
  • Umubyeyi AN, Martin A, Zissis G, Struelens M, Karita E, Portaels F. Evaluation of the resazurin microtiter assay for rapid detection of ofloxacin resistance in M. tuberculosis. Int J Tuberc Lung Dis 2006; 10(7): 808-811.
  • Van Damme W, Kober K, Laga M. The real challenges for scaling up ART in sub-Saharan Africa. AIDS 2006; 20(5): 653-656.
  • Van den Bergh R, Vanham G, Raes G, De Baetselier P, Colebunders R. Mycobacterium-associated immune reconstitution disease: macrophages running wild? [reflection and reaction]. Lancet Infect Dis 2006; 6(1): 2-3.
  • Van den Bosch GA, Van Gulck E, Ponsaerts P, Nijs G, Lenjou M, Apers L, Kint I, Heyndrickx L, Vanham G, Van Bockstaele DR, Berneman ZW, Van Tendeloo VFI. Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells. J Immunother 2006; 29(5): 512-523.
  • Vandepitte J, Lyerla R, Dallabetta G, Crabbé F, Alary M, Buvé A. Estimates of the number of female sex workers in different regions of the world. Sex Transm Infect 2006; 82(Suppl.III): iii18-iii25.
  • Van Deun A, Aung KJM, Hamid Salim A, Ali MA, Naha MS, Das PK, Hossain MA, Declercq E. Extension of the intensive phase reduces unfavourable outcomes with the 8-month thioacetazone regimen. Int J Tuberc Lung Dis 2006; 10(11): 1255-1261.
  • Van Geertruyden JP, Mulenga M, Kasongo W, Polman K, Colebunders R, Kestens L, D'Alessandro U. CD4 T-cell count and HIV-1 infection in adults with uncomplicated malaria. J Acquir Immun Defic Syndr 2006; 43(3): 363-367.
  • Van Geertruyden JP, Mulenga M, Mwananyanda L, Chalwe V, Moerman F, Chilengi R, Kasongo W, Van Overmeir C, Dujardin JC, Colebunders R, Kestens L, D'Alessandro U. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis 2006; 194(7): 917-925.
  • Van Gulck E, Ponsaerts P, Heyndrickx L, Vereecken K, Moerman F, De Roo A, Colebunders R, Van den Bosch G, Van Bockstaele DR, Van Tendeloo VFI, Allard S, Verrier B, Maranon C, Hoeffel G, Hosmalin A, Berneman ZW, Vanham G. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 2006; 107(5): 1818-1827.
  • Vanham G, Van den Bosch GA, Ponsaerts P, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VFI. Cellular immunotherapy for cytomegalovirus and HIV-1 infection. J Immunother 2006; 29(2): 107-121.
 

2005

  • Ablordey A, Hilty M, Stragier P, Swings J, Portaels F. Comparative nucleotide sequence analysis of polymorphic variable-number tandem-repeat loci in Mycobacterium ulcerans. J Clin Microbiol 2005; 43: 5281-5284.
  • Ablordey A, Kotlowski R, Swings J, Portaels F. PCR amplification with primers based on IS2404 and GC-Rich repeated sequence reveals polymorphism in Mycobacterium ulcerans. J Clin Microbiol 2005; 43: 448-451.
  • Ablordey A, Swings J, Hubans C, Chemlal K, Locht C, Portaels F, Supply P. Multilocus variable-number tandem repeat typing of Mycobacterium ulcerans. J Clin Microbiol 2005; 43: 1546-1551.
  • Arend SM, de Haas P, Leyten E, Rosenkrands I, Rigouts L, Andersen P, Mijs W, van Dissel JT, van Soolingen D. ESAT-6 and CFP-10 in clinical versus environmental isolates of Mycobacterium kansasii. J Infect Dis 2005; 191: 1301-1310.
  • Ariën KK. Relative replicative fitness of diverse human immunodeficiency viruses; implication for the individual and the pandemic [dissertation]. Antwerpen: Universiteit Antwerpen, Faculteit Farmaceutische, Biomedische en Diergeneeskundige Wetenschappen, 2005: 203 pp.
  • Ariën KK, Abraha A, Quiñones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005; 79: 8979-8990.
  • Ariën KK, Troyer RM, Gali Y, Colebunders R, Arts EJ, Vanham G. Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time. AIDS 2005; 19: 1555-1564.
  • Baiden F, Remes P, Baiden R, Williams J, Hodgson A, Boelaert M, Buvé A. Voluntary counseling and HIV testing for pregnant women in the Kassena-Nankana district of northern Ghana: is couple counseling the way forward? AIDS Care 2005; 17: 648-657.
  • Bonnet M, Sizaire V, Kebede Y, Janin A, Doshetov D, Mirzoian B, Arzumanian A, Muminov T, Iona E, Rigouts L, Rüsch-Gerdes S, Varaine F. Does one size fit all? Drug resistance and standard treatments: results of six tuberculosis programmes in former Soviet countries. Int J Tuberc Lung Dis 2005; 9: 1147-1154.
  • Cardoso Leão S, Bernardelli A, Cataldi A, Zumarraga M, Robledo J, Realpe T, Mejía GI, da Silva Telles MA, Chimara E, Velazco M, Fernandez J, Rodrigues PA, Guerrero MI, León CI, Porras TB, Rastogi N, Goh KS, Suffys P, da Silva Rocha A, dos Santos Netto D, Ritacco V, López B, Barrera L, Palomino JC, Martin A, Portaels F. Multicenter evaluation of mycobacteria identification by PCR restriction enzyme analysis in laboratories from Latin America and the Caribbean. J Microbiol Meth 2005; 61: 193-199.
  • Chemlal K, Shamputa IC, El Aila N, Rigouts L, Portaels F. Restriction fragment length polymorphism (RFLP); application for mycobacteria typing. In: Fuchs J, Podda M, editors. Encyclopedia of medical genomics and proteomics. [New York]: Marcel Dekker, 2005: 1136-1141.
  • Colebunders R, Hodossy B, Burger D, Daems T, Roelens K, Coppens M, Van Bulck B, Jacquemyn Y, Van Wijngaerden E, Fransen K. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk [research letter]. AIDS 2005; 19: 1912-1915.
  • De Baets AJ, Edidi BS, Kasali MJ, Beelaert G, Schrooten W, Litzroth A, Kolsteren P, Denolf D, Fransen K. Pediatric human immunodeficiency virus screening in an African district hospital. Clin Diagn Lab Immunol 2005; 12: 86-92.
  • Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Portaels F. Buruli ulcer recurrence, Benin. Emerg Infect Dis 2005; 11: 584-589.
  • Diaz T, Buvé A. New strategies for HIV/AIDS surveillance in resource-constrained countries. AIDS 2005; 19(Suppl.2): 73 pp.
  • Dieye TN, Vereecken C, Diallo AA, Ondoa P, Diaw PA, Camara M, Karam F, Mboup S, Kestens L. Absolute CD4 T-cell counting in resource-poor settings; direct volumetric measurements versus bead-based clinical flow cytometry instruments. J Acquir Immun Defic Syndr 2005; 39: 32-37.
  • Janssens P, Pattyn S, Meyers W, Portaels F. Buruli ulcer: an historical overview with updating to 2005. Bull Séances Acad R Sci Outre Mer 2005; 51(3): 265-299.
  • Johnson RC, Makoutodé M, Sopoh GE, Elsen P, Gbovi J, Pouteau LH, Meyers WM, Boko M, Portaels F. Buruli ulcer distribution in Benin [letter]. Emerg Infect Dis 2005; 11: 500-501.
  • Johnson PDR, Stinear T, Small PLC, Plushke G, Merritt RW, Portaels F, Huygen K, Hayman JA, Asiedu K. Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2005; 2: 282-286.
  • Johnson RC, Sopoh GE, Boko M, Zinsou C, Gbovi J, Makoutode M, Portaels F. Distribution de l'infection à Mycobacterium ulcerans (Ulcère de Buruli) dans la commune de Lalo au Bénin. Trop Med Int Health 2005; 10: 863-871.
  • Leão SC, Mello Sampaio JL, Martin A, Palomino JC, Portaels F. Profiling Mycobacterium ulcerans with hsp65 [letter]. Emerg Infect Dis 2005; 11: 1795-1796.
  • Lemus D, Montoro E, Echemendia M, Yzquierdo SL, Martin A, Portaels F, Palomino JC. Nuevos métodos para la detección rápida de la resistencia en Mycobacterium tuberculosis. Biotecnol Aplic 2005; 22: 306-308.
  • Martin A, Montoro E, Lemus D, Simboli N, Morcillo N, Valesco M, Chauca J, Barrera L, Ritacco V, Portaels F, Palomino JC. Milticenter evaluation of the nitrate reductase assay for drug resistance detection of Mycobacterium tuberculosis. J Microbiol Meth 2005; 63: 145-150.
  • Martin A, Morcillo N, Lemus D, Montoro E, da Silva Telles MA, Simboli N, Pontino M, Porras T, León C, Velasco M, Chacon L, Barrera L, Ritacco V, Portaels F, Palomino JC. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int J Tuberc Lung Dis 2005; 9: 901-906.
  • Martin A, Palomino JC, Portaels F. Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays. J Clin Microbiol 2005; 43: 1612-1616.
  • McCormack S, Jespers V, Low-Beer N, Gabe R, Kaganson N, Chapman A, Nunn A, Lacey C, Van Damme L. A dose-ranging phase I study of dextrin sulphate, a vaginal microbicide, in HIV-negative and HIV-positive female volunteers. Sex Transm Dis 2005; 32: 765-770.
  • Meulemans H, Van Ouytsel J, Rigouts L, Mortelmans D, Heunis C, Matebesi Z, van Rensburg D. Social capital and community TB care in the Free State, South Africa. Acta Acad Suppl 2005; 1: 128-153.
  • Mokhethi Z, van der Spoel-van Dijk A, van der Zanden A, Rigouts L. High strain diversity among isoniazid-resistant M. tuberculosis isolates from the Free State and Northern Cape provinces. Acta Acad Suppl 2005; 1: 110-127.
  • Montoro E, Lemus D, Echemendia M, Martin A, Portaels F, Palomino JC. Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2005; 55: 500-505.
  • Njai HF. The biological importance of human immunodeficiency virus type 1 (HIV-1) circulating recombinant form (CRF) CRF02_AG [dissertation]. Brussel: Vrije Universiteit Brussel, Faculty of Sciences, Institute for Molecular Biology/Biotechnology, Laboratory of Cellular and Molecular Immunology, 2005: 172 pp.
  • Njai HF, Lewi PJ, Janssen CGM, Garcia S, Fransen K, Kestens L, Vanham G, Janssen PAJ. Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells. Antiviral Ther 2005; 10: 255-262.
  • Ondoa P, Koblavi-Deme S, Borget MY, Nolan ML, Nkengasong JN, Kestens L. Assessment of CD8+ T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d'Ivoire. Clin Exp Immunol 2005; 140: 138-148.
  • Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, Longatto Filho A, Milanezi F, Schmitt FC, Meyers WM, Portaels F, Silva MT, Pedrosa J. Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun 2005; 73: 6299-6310.
  • Palomino JC. Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability. Eur Resp J 2005; 26: 339-350.
  • Pirard M, Iihoshi N, Boelaert M, Basanta P, López F, Van der Stuyft P. The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region. Transfusion 2005; 45: 554-561.
  • Porras TB, León CI, Guerrero MI, Martin A, Portaels F, Palomino JC. Evaluación de métodos fenotípicos y genotípicos para la detección de farmacorresistencia de Mycobacterium tuberculosis. Biomédica 2005; 25: 22-33.
  • Portaels F. Le partenariat avec les pays africains pour un meilleur contrôle de la tuberculose et de l'ulcère de Buruli. Bull Séances Acad R Sci Outre Mer 2004; 50: 271-282.
  • Raes G, Brys L, Dahal BK, Brandt J, Grooten J, Brombacher F, Vanham G, Noel W, Bogaert P, Boonefaes T, Kindt A, Van den Bergh R, Leenen PJM, De Baetselier P, Ghassabeh GH. Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leucocyte Biol 2005; 77: 321-327.
  • Ramjee G, Williams B, Gouws E, Van Dyck E, De Deken B, Abdool Karim S. The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. J Acquir Immun Defic Syndr 2005; 39: 333-339.
  • Rigouts L, Portaels F. Challenges to effective control of tuberculosis and drug resistance in African countries. Acta Acad Suppl 2005; 1: 56-81.
  • Símboli N, Takiff H, McNerney R, López B, Martin A, Palomino JC, Barrera L, Ritacco V. In-house phage amplification assay is a sound alternative for detecting rifampin-resistant Mycobacterium tuberculosis in low-resource settings. Antimicrob Agents Chemother 2005; 49: 425-427.
  • Stragier P, Ablordey A, Meyers WM, Portaels F. Genotyping Mycobacterium ulcerans and Mycobacterium marinum by using mycobacterial interspersed repetitive units. J Bacteriol 2005; 187: 1639-1647.
  • Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, Krizan RW, Toossi Z, Colebunders RL, Jensen MA, Mullins JI, Vanham G, Arts EJ. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 2005; 79: 9006-9018.
  • Vaerewijck MJM, Huys G, Palomino JC, Swings J, Portaels F. Mycobacteria in drinking water distribution systems: ecology and significance for human health. FEMS Microbiol Rev 2005; 29: 911-934.
  • Van den Bosch GA, Ponsaerts P, Nijs G, Lenjou M, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VFI. Ex vivo induction of viral antigen-specific CD8+ T cell responses using mRNA-electrophorated CD40-activated B cells. Clin Exp Immunol 2005; 139: 458-467.
  • Vandenbruaene M, Ostyn B, Crucitti T, De Schrijver K, Sasse A, Sergeant M, Van Dyck E, Van Esbroeck M, Moerman F. Lymphogranuloma venereum outbreak in men who have sex with men (MSM) in Belgium, January 2004 to July 2005 [electronic only]. Eurosurveillance Weekly 2005; 10(9): 2 pp.
  • van der Spoel-van Dijk A, Mokhethi Z, Khumalo M, Shamputa C, Matebesi Z, van Rensburg D, Portaels F, Rigouts L. DNA fingerprinting analyses of M. tuberculosis-complex isolates from the Free State, South Africa, as part of a multidisciplinary study. Acta Acad Suppl 2005; 1: 82-109.
  • van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O, Fleischer B, Wansbrough-Jones MH, Johnson PDR, Portaels F, van der Graaf WTA, Asiedu K. Mycobacterium ulcerans disease. Bull World Health Organ 2005; 83: 785-791.
  • Van Deun A, Kim SJ, Rieder HL. Will the bleach method keep its promise in sputum smear microscopy? [letter]. Int J Tuberc Lung Dis 2005; 9: 700.
  • Van Deun A, Rieder HL, Kim SJ, Chiang CY, Caminero J, Aït-Khaled N, Hinderaker SG, Fujiwara PI, Trébucq A, Enarson DA, Boillot F, Tuberculosis Division. Tuberculosis bacteriology, priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis 2005; 9: 355-361.
  • Van Deun A, Salim AH, Das PK, Bastian I, Portaels F. Should isoniazid and clofazimine be used to treat multidrug-resistant tuberculosis? [reply]. Int J Tuberc Lung Dis 2005; 9: 232-233.
  • Van Deun A, Salim AH, Aung KJM, Hossain MA, Chambugonj N, Hye MA, Kawria A, Declercq E. Performance of variations of carbolfuchsin staining of sputum smears for AFB under field conditions. Int J Tuberc Lung Dis 2005; 9: 1127-1133.
  • van Rensburg D, Meulemans H, Rigouts L, editors. Tuberculosis: multidisciplinary approaches to research, policy and practice. Bloemfontein: UFS-SASOL Library, 2005: 353 pp. (Acta Academica; Suppl.1).
  • Walsh DS, Meyers WM, Portaels F, Lane JE, Mongkolsirichaikul D, Hussem K, Gosi P, Myint KSA. High rates of apoptosis in human Mycobacterium ulcerans culture-positive Buruli ulcer skin lesions. Am J Trop Med Hyg 2005; 73: 410-415.
 

2004

  • Daniel AK, Lee RE, Portaels F, Small PLC. Analysis of Mycobacterium species for the presence of a macrolide toxin, mycolactone. Infect Immun 2004; 72: 123-132.
  • Davis D, Donners H, Willems B, Lövgren-Bengtsson K, Akerblom L, Vanham G, Barnett S, Morein B, Heeney JL, van der Groen G. Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120. Vaccine 2004; 22: 747-754.
  • Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Scott JT, Dramaix M, Portaels F. Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health 2004; 9: 1297-1304.
  • Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Wit S, Florence E, Fransen K, García Ribas S, Marissens D, Moutschen M, Vaira D, Zissis G, Van Ranst M, Van Wijngaerden E, Vandamme AM. Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response [letter]. J Acquir Immun Defic Syndr 2004; 37: 1664-1666.
  • Eddyani M, Ofori-Adjei D, Teugels G, De Weirdt D, Boakye D, Meyers WM, Portaels F. Potential role for fish in transmission of Mycobacterium ulcerans disease (Buruli ulcer): an environmental study. Appl Environ Microbiol 2004; 70: 5679-5681.
  • Eyob G, Guebrexabher H, Lemma E, Wolday D, Gebeyehu M, Abate G, Rigouts L, van Soolingen D, Fontanet A, Sanders E, Dorigo-Zetsma JW. Drug susceptibility of Mycobacterium tuberculosis in HIV-infected and -uninfected Ethiopians and its impact on outcome after 24 months of follow-up. Int J Tuberc Lung Dis 2004; 8: 1388-1391.
  • Falkinham JO, Nichols G, Bartram J, Dufour A, Portaels F. Natural ecology and survival in water of mycobacteria of potential public health significance. In: Pedley S, Bartram J, Rees G, Dufour A, Cotruvo JA, editors. Pathogenic Mycobacteria in water; a guide to public health consequences, monitoring and management. London: IWA Publishing; Geneva: World Health Organization (WHO), 2004: 15-25. (Emerging Issues in Water and Infectious Disease Series).
  • Glynn JR, Caraël M, Buvé A, Anagonou S, Zekeng L, Kahindo M, Musonda R. Does increased general schooling protect against HIV infection? A study in four African cities. Trop Med Int Health 2004; 9: 4-14.
  • Jennes W, Kestens L. Unprotected sex and alloimmune activation [letter]. Lancet 2004; 363: 1474.
  • Jennes W, Vereecken C, Fransen K, De Roo A, Kestens L. Disturbed secretory capacity for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in progressive HIV infection. AIDS Res Hum Retroviruses 2004; 20: 1087-1091.
  • Jennes W, Vuylsteke B, Borget MY, Traoré-Ettiegne V, Maurice C, Nolan M, Nkengasong JN, Kestens L. HIV-specific T helper resonses and frequency of exposure among HIV-exposed seronegative female sex workers in Abdijan, Côte d'Ivoire. J Infect Dis 2004; 189: 602-610.
  • Karlsson RK, Jennes W, Page-Shafer K, Nixon DF, Shacklett BL. Poorly soluble peptides can mimic authentic ELISPOT responses. J Immunol Methods 2004; 285: 89-92.
  • Kibadi K, Muyembe T, Phanzu D, Mbala L, Meyers WM, Portaels F. Association large ulcère de Buruli thoraco-abdominal et pleurésie massive homolatérale: aspects diagnostiques et difficultés de prise en charge, à propos d'un cas. Méd Afrique Noire 2004; 51: 643-648.
  • Koblavi-Dème S, Kestens L, Hanson D, Otten RA, Borget MY, Bilé C, Wiktor SZ, Roels TH, Chorba T, Nkengasong JN. Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Côte d'Ivoire. AIDS 2004; 18: 413-419.
  • Kotlowski R, Shamputa IC, El Aila NA, Sajduda A, Rigouts L, Van Deun A, Portaels F. PCR-based genotyping of Mycobacterium tuberculosis with new GC-rich repeated sequences and IS6110 inverted repeats used as primers. J Clin Microbiol 2004; 42: 372-377.
  • Leão SC, Martin A, Mejia GI, Palomino JC, Robledo J, da Silva Telles MA, Portaels F. Practical handbook for the phenotypic and genotypic identification of mycobacteria. [s.l.]: [s.n.], 2004: 164 pp.
  • Maerten P, Shen C, Colpaert S, Liu Z, Bullens DAM, Van Assche G, Penninckx F, Geboes K, Vanham G, Rutgeerts P, Ceuppens JL. Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models. Clin Exp Immunol 2004; 135: 310-317.
  • Martin-Casabona N, Bahrmand AR, Bennedsen J, Ostergaard Thomsen V, Curcio M, Fauville-Dufaux M, Feldman K, Havelkova M, Katila ML, Köksalan K, Pereira MF, Rodrigues F, Pfyffer GE, Portaels F, Rosselló Urgell J, Rüsch-Gerdes S, Tortoli E, Vincent V, Watt B. Non-tuberculous mycobacteria: patterns of isolation; a multi-country retrospective survey. Int J Tuberc Lung Dis 2004; 8: 1186-1193.
  • Mosoko JJ, Delvaux T, Glynn JR, Zekeng L, Macauley I, Buvé A. Induced abortion among women attending antenatal clinics in Yaounde, Cameroon. East Afr Med J 2004; 81: 71-24.
  • Nichols G, Ford T, Bartram J, Dufour A, Portaels F. Introduction. In: Pedley S, Bartram J, Rees G, Dufour A, Cotruvo JA, editors. Pathogenic Mycobacteria in water; a guide to public health consequences, monitoring and management. London: IWA Publishing; Geneva: World Health Organization (WHO), 2004: 1-14. (Emerging Issues in Water and Infectious Disease Series).
  • Noeske J, Kuaban C, Rondini S, Sorlin P, Ciaffi L, Mbuagbaw J, Portaels F, Pluschke G. Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg 2004; 70: 520-526.
  • Palomino JC. Development of rapid methods for drug resistance detection in Mycobacterium tuberculosis [dissertation]. Gent: Universiteit Gent, Vakgroep Biochemie, 2004: 225 pp.
  • Palomino JC, Martin A, Portaels F. A microplate indicator-based method for determining the susceptibility of multidrug-resistant Mycobacterium tuberculosis to antimicrobial agents [letter]. Int J Tuberc Lung Dis 2004; 8: 1510-1511.
  • Portaels F. Les atteintes osseuses dans l'ulcère de Buruli: évolution clinique, étude microbiologique et identification de facteurs de risque. Bull ALLF 2004; 15: 39-41.
  • Portaels F. Mycobactéries et pays tropicaux: de l'environnement à l'homme. Méd Trop 2004; 64: 219-220.
  • Portaels F, Aguiar J, Debacker M, Guédénon A, Steunou C, Zinsou C, Meyers WM. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004; 72: 62-65.
  • Sajduda A, Brzostek A, Poplawska M, Rastogi N, Sola C, Augustynowicz-Kopec E, Zwolska Z, Dziadek J, Portaels F. Molecular epidemiology of drug-resistant Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Poland: a 1-year study. Int J Tuberc Lung Dis 2004; 8: 1448-1457.
  • Schmid GP, Buvé A, Calleja JG, Ghys PD, Boerma JT. Unsafe injections and transmission of HIV-1 in sub-Saharan Africa [reply]. Lancet 2004; 363: 1649-1650.
  • Schmid GP, Buvé A, Mugyenyi P, Garnet GP, Hayes RJ, Williams BG, Calleja JG, De Cock KM, Whitworth JA, Kapiga SH, Ghys PD, Hankins C, Zaba B, Heimer R, Boerma JT. Transmission of HIV-1 injection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet 2004; 363: 482-488.
  • Scott JT, Johnson RC, Aguiar J, Debacker M, Kestens L, Guedenon A, Gryseels B, Portaels F. Schistosoma haematobium infection and Buruli ulcer [letter]. Emerg Infect Dis 2004; 10: 551-552.
  • Scott JT, Vereecken K, Diakhaté MM, Vanagt T, Sambou V, Diop M, Ly A, Vercruysse J, Gryseels B, Kestens L. Are the cellular immune responses of children and adults with Schistosoma mansoni infection intrinsically different? Cytokines produced ex vivo in response to antigens and mitogens. Parasite Immunol 2004; 26: 29-36.
  • Shamputa IC, Rigouts L, Eyongeta LA, El Aila NA, Van Deun A, Salim AH, Willery E, Locht C, Supply P, Portaels F. Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients. J Clin Microbiol 2004; 42: 5528-5536.
  • Shamputa IC, Rigouts L, Portaels F. Molecular genetic methods for diagnosis and antibiotic resistance detection of mycobacteria from clinical specimens. APMIS 2004; 112: 728-752.
  • Vahratian A, Buekens P, Delvaux T, Boutsen M, Wang Y, Kupper LL. Birthweight differences among infants of North African immigrants and Belgians in Belgium. Eur J Public Health 2004; 14: 381-383.
  • Van den Bosch G, Ponsaerts P, Van Tendeloo V, Van Bockstaele D, Vanham G, Berneman ZN. Actieve immunotherapie voor HIV-1-infectie. Tijdschr Geneeskd 2004; 60: 1555-1564.
  • Van Deun A, Salim AH, Daru P, Das APK, Aung KJM, Hossain MA, Rigouts L, Fissette K, Portaels F. Drug resistance monitoring: combined rates may be the best indicator of programme performance. Int J Tuberc Lung Dis 2004; 8: 23-30.
  • Van Deun A, Salim AH, Das APK, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8: 560-567.
  • Van Herrewege Y. Exploring an in vitro model for prevention and post-exposure prophylaxis (PEP) of sexual HIV transmission [dissertation]. Antwerpen: Universiteit Antwerpen, Faculteit Geneeskunde, 2004: 157 pp.
  • Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, Lewi P, Vanham G, Janssen P. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004; 48: 337-339.
  • Van Herrewege Y, Vanham G, Michiels J, Fransen K, Kestens L, Andries K, Janssen P, Lewi P. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob Agents Chemother 2004; 48: 3684-3689.
  • Vansnick E, de Rijk P, Vercammen F, Geysen D, Rigouts L, Portaels F. Newly developed primers for the detection of Mycobacterium avium subspecies paratuberculosis. Vet Microbiol 2004; 100: 197-204.
  • Vuylsteke B. Current status of syndromic management of sexually transmitted infections in developing countries [editorial]. Sex Transm Infect 2004; 80: 333-334.
  • Vuylsteke B, Traore M, Mah-Bi G, Konan Y, Ghys P, Diarra J, Laga M. Quality of sexually transmitted infections services for female sex workers in Abidjan, Côte d'Ivoire. Trop Med Int Health 2004; 9: 638-643.
  • Zahara S, Salim A, Grillone S, Pattyn SR. Résultats d'une campagne d'élimination de la lèpre (CEL) à Anjouan (Union des Comores). Bull ALLF 2004; 14: 8-10.
  • Ziermann R, Celis L, Derdelinckx I, Lambert C, Veeck J, Rizzo MG, Vanderborght B, Zissis G, Clumeck N, Fransen K, Vaira D, Hendricks D, Van Laethem K, Vandamme AM, Schmit JC, Knechten H, De Luca A, Louwagie J, Segers P, De Boeck K, Pottel H, De Brauwer A, Hulstaert F. Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system. J Clin Virol 2004; 31(Suppl.1): S7-S15.
 

2003

  • Aujoulat I, Johnson C, Zinsou C, Guédénon A, Portaels F. Psychosocial aspects of health seeking behaviours of patients with Buruli ulcer in southern Benin. Trop Med Int Health 2003; 8: 750-759.
  • Buvé A, Kalibala S, McIntyre J. Stronger health systems for more effective HIV/AIDS prevention and care. Int J Health Plann Manag 2003; 18(Suppl.1): S41-S51.
  • Buzingo T, Sanders M, Masabo JP, Nyandwi S, Van Deun A. Systematic restaining of sputum smears for quality control is useful in Burundi. Int J Tuberc Lung Dis 2003; 7: 439-444.
  • Carmoi T, Josse R, Dexemple P, Portaels F, Jeandel P. Les tréponématoses endémiques et l'ulcère de Buruli: deux ostéomyélites exotiques d'actualité. Rev Rhum 2003; 70: 119-131.
  • Chemlal K, Portaels F. Molecular diagnosis of nontuberculous mycobacteria. Curr Opin Infect Dis 2003; 16: 77-83.
  • Crucitti T, Van Dyck E, Tehe A, Abdellati S, Vuylsteke B, Buvé A, Laga M. Comparison of culture and different PCR assays for detection of Trichomonas vaginalis in self collected vaginal swab specimens. Sex Transm Infect 2003; 79: 393-398.
  • Davis D, Donners H, Willems B, Vermoesen T, Heyndrickx L, Colebunders R, van der Groen G. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases. J Med Virol 2003; 71: 332-342.
  • Debacker M, Zinsou C, Aguiar J, Meyers WM, Portaels F. First case of Mycobacterium ulcerans disease (Buruli ulcer) following a human bite [electronic only]. Clin Infect Dis 2003; 36: e67-e68.
  • Delvaux T, Buekens P, Thoumsin H, Dramaix M, Collette J. Cord C-peptide and insulin-like growth factor-I, birth weight, and placenta weight among North African and Belgian neonates. Am J Obstet Gynecol 2003; 189: 1779-1784.
  • Delvaux T, Crabbé F, Seng S, Laga M. The need for family planning and safe abortion services among women sex workers seeking STI care in Cambodia. Reprod Health Matt 2003; 11(21): 88-95.
  • Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Schouwer K, De Wit S, Fransen K, Ribas SG, Moutschen M, Vaira D, Zissis G, Van Ranst M, Van Wijngaerden E, Vandamme AM. Performance of the VERSANT (R) HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes. FEMS Immunol Med Microbiol 2003; 39: 119-124.
  • Diomandé FVK, Bissagnéné E, Nkengasong JN, Maurice C, Monga B, Laga M, Nolan ML. The most efficient use of resources to identify those in need of antiretroviral treatment in Africa: empirical data from Côte d'Ivoire's Drug Access Initiative. AIDS 2003; 17(Suppl.3): S87-S93.
  • Donners H. Neutralizing antibodies in HIV-infected or HIV-vaccinated individuals [dissertation]. Antwerpen: Universiteit Antwerpen, Faculteit Wetenschappen, Biochemie, 2003: 155 pp.
  • Donners H, Davis D, Willems B, van der Groen G. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions. J Med Virol 2003; 69: 173-181.
  • Donners H, Vermoesen T, Willems B, Davis D, van der Groen G. The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases. Vaccine 2003; 22: 104-111.
  • García Ribas S, Ondoa P, Schüpbach J, van der Groen G, Fransen K. Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals. J Virol Methods 2003; 113: 29-34.
  • Glynn JR, Caraël M, Buvé A, Musonda RM, Kahindo M, Study Group on Heterogeneity of HIV Epidemics in African Cities. HIV risk in relation to marriage in areas with high prevalence of HIV infection. J Acquir Immun Defic Syndr 2003; 33: 526-535.
  • Jennes W. Correlates of protective immunity among HIV-exposed seronegative female sex workers in Abidjan, Côte d'Ivoire [dissertation]. Antwerpen: Universiteit Antwerpen, Faculteit Wetenschappen, Biochemie, 2003: 164 pp.
  • Jennes W, Sawadogo S, Koblavi-Dème S, Vuylsteke B, Maurice C, Roels TH, Chorba T, Nkengasong JN, Kestens L. Cellular human immunodeficiency virus (HIV)- protective factors: a comparison of HIV-exposed seronegative sex workers and female blood donors in Abidjan, Côte d'Ivoire. J Infect Dis 2003; 187: 206-214.
  • Katzenstein D, Laga M, Moatti JP. The evaluation of the HIV/AIDS drug access initiatives in Côte d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa. AIDS 2003; 17(Suppl.3): 113 pp.
  • Katzenstein D, Laga M, Moatti JP. The evaluation of the HIV/AIDS drug access initiatives in Côte d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa [editorial]. AIDS 2003; 17(Suppl.3): S1-S4.
  • Koblavi-Dème S, Maran M, Kabran N, Borget MY, Kalou M, Kestens L, Maurice C, Sassan-Morokro M, Ekpini ER, Roels TH, Chorba T, Nkengasong JN. Changes in level of immune activation and reconstitution among HIV-1-infected Africans receiving antiretroviral therapy. AIDS 2003; 17(Suppl.3): S17-S22.
  • Lafort Y, Sawadogo Y, Delvaux T, Vuylsteke B, Laga M. Should family planning clinics provide clinical services for sexually transmitted infections? A case study from Côte d'Ivoire. Trop Med Int Health 2003; 8: 552-560.
  • Lambert ML, Hasker E, Van Deun A, Roberfroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis 2003; 3: 282-287.
  • Lambert ML, Hasker E, Van Deun A, Roberfroid D, Van der Stuyft P. Rifampin and recurrence of tuberculosis among patients infected with HIV [reply]. Clin Infect Dis 2003; 37: 1719-1720.
  • Mahendradhata Y, Lambert ML, Van Deun A, Matthys F, Boelaert M, Van der Stuyft P. Strong general health care systems: a prerequisite to reach global tuberculosis control targets. Int J Health Plann Manag 2003; 18(Suppl.1): S53-S65.
  • Martin A, Camacho M, Portaels F, Palomino JC. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother 2003; 47: 3616-3619.
  • Meyers WM, Portaels F. Buruli ulcer: Mycobacterium ulcerans infection; 4th ed. In: Warrell DA, Cox TM, Firth JD, Benz EJ, editors. Oxford textbook of medicine. Oxford: Oxford University Press, 2003; Vol.1: 583-585.
  • Muwonga J, Edidi S, Atibu L, Mama N, Lepira F, Tahiri M, Beelaert G, Fransen K, Colebunders R. Accessibilité et contrôle de qualité au Laboratoire National de Référence VIH et IST du PNLS en RDC. Congo Méd 2003; 3: 823-825.
  • Mve-Obiang A, Lee RE, Portaels F, Small PLC. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun 2003; 71: 774-783.
  • Ondoa P, Vereecken C, Fransen K, Colebunders R, van der Groen G, Heeney JL, Kestens L. Human and simian immunodeficiency virus-infected chimpanzees do not have increased intracellular levels of beta-chemokines in contrast to infected humans. J Med Virol 2003; 69: 297-305.
  • Portaels F, Scott J, Martin A, Meyers WM, Elsen P. Mise en évidence de Mycobacterium ulcerans chez des insectes aquatiques, des poissons et des mollusques échantillonnés dans l'environnement au Bénin. Bull ALLF 2003; 13: 30-31.
  • Portaels F, Zinsou C, Aguiar J, Debacker M, de Biurrun E, Guédénon A, Josse R, Lagarrigue V, Silva MT, Steunou C, Meyers WM. Les atteintes osseuses dans l'ulcère de Buruli: à propos de 73 cas. Bull Séances Acad R Sci Outre Mer 2003; 49: 161-190.
  • Pszolla N, Robindra Sarkar M, Strecker W, Kern P, Kinzl L, Meyers WM, Portaels F. Buruli ulcer: a systemic disease. Clin Infect Dis 2003; 37: e78-e82.
  • Scott JT, Diakhaté M, Vereecken K, Fall A, Diop M, Ly A, De Clercq D, de Vlas SJ, Berkvens D, Kestens L, Gryseels B. Human water contacts patterns in Schistosoma mansoni epidemic foci in northern Senegal change according to age, sex and place of residence, but are not related to intensity of infection. Trop Med Int Health 2003; 8: 100-108.
  • Stop TB Working Group on DOTS-Plus for MDR-TB. A prioritised research agenda for DOTS-Plus for multidrug-resistant tuberculosis (MDR-TB). Int J Tuberc Lung Dis 2003; 7: 410-414.
  • Van Blerk M, Bernier M, Bossuyt X, Chatelain B, D'Hautcourt JL, Demanet C, Kestens L, Van Bockstaele D, Crucitti T, Libeer JC. National external quality assessment scheme for lymphocyte immunophenotyping in Belgium. Clin Chem Lab Med 2003; 41: 323-330.
  • Van Damme L, Rees H, Ramjee G, Laga M, Mâsse B. Need for a true placebo for vaginal microbicide efficacy trials [reply]. Lancet 2003; 361: 786.
  • Van Deun A. External quality assessment of sputum smear microscopy: a matter of careful technique and organisation [editorial]. Int J Tuberc Lung Dis 2003; 7: 507-508.
  • Vuylsteke B. Strategies for the control of sexually transmitted infections in women in developing countries [dissertation]. Gent: Universiteit Gent, Faculteit Geneeskunde en Gezondheidswetenschappen, Vakgroep Maatschappelijke Gezondheidkunde, 2003: 212 pp. (Monografieën van de Vakgroep Maatschappelijke Gezondheidkunde, Universiteit Gent).
  • Vuylsteke BL, Ettiègne-Traoré V, Anoma CK, Bandama C, Ghys PD, Maurice CE, Van Dyck E, Wiktor SZ, Laga M. Assessment of the validity of and adherence to sexually transmitted infection algorithms at a female sex worker clinic in Abidjan, Côte d'Ivoire. Sex Transm Dis 2003; 30: 284-291.
  • Vuylsteke B, Ghys PD, Traoré M, Konan Y, Mah-Bi G, Maurice C, Soroh D, Diarra JN, Roels TH, Laga M. HIV prevalence and risk behavior among clients of female sex workers in Abidjan, Côte d'Ivoire. AIDS 2003; 17: 1691-1694.
  • Weber J, Rangel HR, Chakraborty B, Marotta ML, Valdez H, Fransen K, Florence E, Connick E, Smith KY, Colebunders RL, Landay A, Kuritzkes DR, Lederman MM, Vanham G, Quiñones-Mateu ME. Role of baseline pol genotype in HIV-1 fitness evolution. J Acquir Immun Defic Syndr 2003; 33: 448-460.
 

2002

  • Balzarini J, Van Herrewege Y, Vanham G. Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS 2002; 16: 2159-2163.
  • Beelaert G, Vercauteren G, Fransen K, Mangelschots M, De Rooy M, Garcia-Ribas S, van der Groen G. Comparative evaluation of eight commercial enzyme linked immunosorbent assays and 14 simple assays for detection of antibodies to HIV. J Virol Methods 2002; 105: 197-206.
  • Bortolotti V, Buvé A. Prophylaxis of opportunistic infections in HIV-infected adults in sub-Saharan Africa: opportunities and obstacles. AIDS 2002; 16: 1309-1317.
  • Boutonnet N, Janssens W, Boutton C, Verschelde JL, Heyndrickx L, Beirnaert E, van der Groen G, Lasters I. Comparison of predicted scaffold-compatible sequence variation in the triple-hairpin structure of human immunodeficiency virus type 1 gp41 with patient data. J Virol 2002; 76: 7598-7606.
  • Buvé A. AIDS in Africa [reply]. Lancet 2002; 360: 1423-1424.
  • Buvé A. HIV epidemics in Africa: what explains the variations in HIV prevalence. IUBMB Life 2002; 53: 193-195.
  • Buvé A, Bishikwabo-Nsarhaza K, Mutangadura G. The spread and effect of HIV-1 infection in sub-Saharan Africa. Lancet 2002; 359: 2011-2017.
  • Camps K, Jorens PG, Demey HE, Pattyn SR, Ieven M. Clinical significance of herpes simplex virus in the lower respiratory tract of critically ill patients. Eur J Clin Microbiol Infect Dis 2002; 21: 758-759.
  • Chemlal K, Huys G, Laval F, Vincent V, Savage C, Gutierrez C, Laneelle MA, Swings J, Meyers WM, Daffe M, Portaels F. Characterization of an unusual mycobacterium: a possible missing link between Mycobacterium marinum and Mycobacterium ulcerans. J Clin Microbiol 2002; 40: 2370-2380.
  • Debacker M, Zinsou C, Aguiar J, Meyers W, Portaels F. Mycobacterium ulcerans disease (Buruli ulcer) following human bite [clinical picture]. Lancet 2002; 360: 1830.
  • Donners H, Willems B, Beirnaert E, Colebunders R, Davis D, van der Groen G. Cross-neutralizing antibodies against primary isolates in African women infected with HIV-1 [letter]. AIDS 2002; 16: 501-503.
  • Espey DK, Djomand G, Diomande I, Dosso M, Saki MZ, Kanga JM, Spiegel RA, Marston BJ, Gorelkin L, Meyers WM, Portaels F, Deming MS, Horsburgh CR. A pilot study of treatment of Buruli ulcer with rifampicin and dapsone. Int J Infect Dis 2002; 6: 60-65.
  • Florence E, Dreezen C, Desmet P, Smets E, Fransen K, Vandercam B, Pelgrom J, Clumeck N, Colebunders R. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study). Antiviral Ther 2002; 6: 255-262.
  • Ghys PD, Diallo MO, Ettiègne-Traoré V, Kal‚ K, Tawil O, Caraël M, Traoré M, Mah-bi G, De Cock KM, Wiktor SZ, Laga M, Greenberg AE. Increase in condom use and decline in HIV and sexually transmitted diseases among female sex workers in Abidjan, Côte d'Ivoire, 1991-1998. AIDS 2002; 16: 251-258.
  • Gómez-Marin JE, León Franco CI, Inirida Guerrero M, Rigouts L, Portaels F. IS6110 fingerprinting of sensitive and resistant strains (1991-1992) of Mycobacterium tuberculosis in Colombia. Mem Inst Oswaldo Cruz 2002; 97: 1005-1008.
  • Jennes W, Kestens L, Nixon DF, Shacklett BL. Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15: the Amplispot assay. J Immunol Methods 2002; 270: 99-108.
  • Jennes W, Sawadogo S, Koblavi-Dème S, Vuylsteke B, Maurice C, Roels TH, Chorba T, Nkengasong JN, Kestens L. Positive association between beta-chemokine-producing T cells and HIV type 1 viral load in HIV-infected subjects in Abidjan, Côte d'Ivoire. AIDS Res Hum Retroviruses 2002; 18: 171-177.
  • Johnson RC, Ifebe D, Hans-Moevi A, Kestens L, Houessou R, Guédénon A, Meyers WM, Portaels F. Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study [letter]. AIDS 2002; 16: 1704-1705.
  • Lagarde E, Caraël M, Auvert B, Buvé A. Concurrency and sexual transmission: a response to the letter by Rothenberg et al. [letter]. AIDS 2002; 16: 679-680.
  • Lowndes CM, Alary M, Meda H, Gnintoungbé CAB, Mukenge-Tshibaka L, Adjovi C, Buvé A, Morison L, Laourou M, Kanhonou L, Anagonou S. Role of core and bridging groups in the transmission dynamics of HIV and STIs in Cotonou, Benin, West Africa. Sex Transm Infect 2002; 78(Suppl.1): i69-i77.
  • Mijs W, de Haas P, Rossau R, Van der Laan T, Rigouts L, Portaels F, van Soolingen D. Molecular evidence to support a proposal to reserve the designation Mycobacterium avium subsp. avium for bird-type isolates and 'M. avium subsp. hominissuis' for the human/porcine type of M. avium. Int J Syst Evol Microbiol 2002; 52: 1505-1518.
  • Mijs W, De Vreese K, Devos A, Pottel H, Valgaeren A, Evans C, Norton J, Parker D, Rigouts L, Portaels F, Reischl U, Watterson S, Pfyffer G, Rossau R. Evaluation of a commercial line probe assay for identification of Mycobacterium species from liquid and solid culture. Eur J Clin Microbiol Infect Dis 2002; 21: 794-802.
  • Mukenge-Tshibaka L, Alary M, Lowndes CM, Van Dyck E, Guédou A, Geraldo N, Anagonou S, Lafia E, Joly JR. Syndromic versus laboratory-based diagnosis of cervical infections among female sex workers in Benin. Sex Transm Dis 2002; 29: 324-330.
  • Nyambi P, Heyndrickx L, Vereecken K, Burda S, De Houwer K, Coppens S, Urbanski M, Williams C, Ndumbe P, Janssens W. Predominance of infection with HIV-1 circulating recombinant form CRF02_AG in major Cameroonian cities and towns [letter]. AIDS 2002; 16: 295-296.
  • Ondoa P, Davis D, Kestens L, Vereecken C, Garcìa Ribas S, Fransen K, Heeney J, van der Groen G. In vitro susceptibility to infection with SIVcpz and HIV-1 is lower in chimpanzee than in human peripheral blood mononuclear cells. J Med Virol 2002; 67: 301-311.
  • Ondoa P, Vingerhoets J, Vereecken C, van der Groen G, Heeney JL, Kestens L. In vitro replication of SIVcpz is suppressed by beta-chemokines and CD8+ T cells but not by natural killer cells of infected chimpanzees. AIDS Res Hum Retroviruses 2002; 18: 373-382.
  • Palomino JC, Martin A, Camacho M, Guerra H, Swings J, Portaels F. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 2720-2722.
  • Pattyn S, Grillone S. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy. Lepr Rev 2002; 73: 245-247.
  • Portaels F, Aguiar J, Debacker M, Steunou C, Zinsou C, Guédénon A, Meyers WM. Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli ulcer). Clin Diagn Lab Immunol 2002; 9: 1389-1391.
  • Scientific considerations for the regulation and clinical evaluation of HIV/AIDS preventive vaccines; report from a WHO-UNAIDS Consultation 13-15 March 2001, Geneva, Switzerland. AIDS 2002; 16: W15-W25.
  • Servais J, Hainaut M, Schmitz V, Maes P, Fransen K, Vaira D, Brichard B, Arendt V, Schneider F, Hemmer R, Schmit JC. Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor. Pediatr Infect Dis J 2002; 21: 214-220.
  • Van Damme L, Jespers V, Van Dyck E, Chapman A. Penile application of dextrin sulphate gel (Emmelle). Contraception 2002; 66: 133-136.
  • Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Abdool Karim SS, Mâsse B, Perriëns J, Laga M, COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360: 971-977.
  • Van Deun A. Periodic or routine susceptibility testing in tuberculosis control [reply]. Int J Tuberc Lung Dis 2002; 6: 177-179.
  • Van Deun A, Salim AH, Cooreman E, Hossain A, Rema A, Chambugonj N, Hye A, Kawria A, Declercq E. Optimal tuberculosis case detection by direct sputum smear microscopy: how much better is more? Int J Tuberc Lung Dis 2002; 6: 222-230.
  • Van Herrewege Y, Penne L, Vereecken C, Fransen K, van der Groen G, Kestens L, Balzarini J, Vanham G. Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission. AIDS Res Hum Retroviruses 2002; 18: 1091-1102.
  • Watson-Jones D, Changalucha J, Gumodoka B, Weiss H, Rusizoka M, Ndeki L, Whitehouse A, Balira R, Todd J, Ngeleja D, Ross D, Buvé A, Hayes R, Mabey D. Syphilis in pregnancy in Tanzania. I. Impact of maternal syphilis on outcome of pregnancy. J Infect Dis 2002; 186: 940-947.
  • Watson-Jones D, Gumodoka B, Weiss H, Changalucha J, Todd J, Mugeye K, Buvé A, Kanga Z, Ndeki L, Rusizoka M, Ross D, Marealle J, Balira R, Mabey D, Hayes R. Syphilis in pregnancy in Tanzania. II. The effectiveness of antenatal syphilis screening and single-dose benzathine penicillin treatment for the prevention of adverse pregnancy outcomes. J Infect Dis 2002; 186: 948-957.
  • Zhong P, Burda S, Urbanski M, Kenfack H, Tongo M, Heyndrickx L, Nanfack A, Shang J, Agyingi L, Zolla-Pazner S, Zekeng L, Nyambi P. HIV type 1 group M clades infecting subjects from rural villages in Equatorial rain forests of Cameroon. J Acquir Immun Defic Syndr 2002; 31: 495-505.
 

2001

  • Adjé CA, Bilé C, Kestens L, Koblavi-Dème S, Ghys PD, Maurice C, Kalou-Bidirou M, Ekpini RE, Llal RB, Roels TH, Wiktor SZ, Nkengasong JN. Lack of effect of chemokine receptor CCR2b gene polymorphism on HIV-1 plasma RNA viral load and immune activation among HIV-1 seropositive female sex workers in Abidjan, Côte d'Ivoire. J Med Virol 2001; 64: 398-401.
  • Alsallami AA, Kotlowski R. Selection of primers for specific detection of Clostridium botulinum types B and E neurotoxin genes using PCR method. Int J Food Microbiol 2001; 69: 247-253.
  • Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1; report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee, Geneva, 21-23 February 2000. AIDS 2001; 15: W1-W25.
  • Auvert B, Buvé A, Ferry B, Caraël M, Morison L, Lagarde E, Robinson NJ, Kahindo M, Chege J, Rutenberg N, Musonda R, Laourou M, Akam E, Study Group on Heterogeneity of HIV Epidemics in African Cities. Ecological and individual level analysis of risk factors for HIV infection in four urban populations in sub-Saharan Africa with different levels of HIV infection. AIDS 2001; 15(Suppl.4): S15-S30.
  • Auvert B, Buvé A, Lagarde E, Kahindo M, Chege J, Rutenberg N, Musonda R, Laourou M, Akam E, Weiss HA, Study Group on Heterogeneity of HIV Epidemics in African Cities. Male circumcision and HIV infection in four cities in sub-Saharan Africa. AIDS 2001; 15(Suppl.4): S31-S40.
  • Bastian I, Rigouts L, Palomino JC, Portaels F. Kanamycin susceptibility testing of Mycobacterium tuberculosis using mycobacterium growth indicator tube and a colorimetric method. Antimicrob Agents Chemother 2001; 45: 1934-1936.
  • Beirnaert E. Broad cross-neutralisation in HIV-infected individuals [dissertation]. Antwerpen: Universiteit Antwerpen, Faculteit Wetenschappen, Departement Biochemie, 2001: 168 pp.
  • Beirnaert E, De Zutter S, Janssens W, van der Groen G. Potent broad cross-neutralizing sera inhibit attachment of primary HIV-1 isolates (groups M and O) to peripheral blood mononuclear cells. Virology 2001; 281: 305-314.
  • Ben Ali A, De Baere R, Van der Auwera G, De Wachter R, Van de Peer Y. Phylogenetic relationships among algae based on complete large-subunit rRNA sequences. Int J Syst Evol Microbiol 2001; 51: 737-749.
  • Bruisten SM, Cairo I, Fennema H, Pijl A, Buimer M, Peerbooms PGH, Van Dyck E, Meijer A, Ossewaarde JM, van Doornum GJJ. Diagnosing genital ulcer disease in a clinic for sexually transmitted diseases in Amsterdam, The Netherlands. J Clin Microbiol 2001; 39: 601-605.
  • Buvé A. Factors determining the differential spread of HIV in sub-Saharan Africa [dissertation]. Antwerpen: Universiteit Antwerpen, Faculteit Medische en Farmaceutische Wetenschappen, 2001: 337 pp.
  • Buvé A. Stronger health systems for more effective HIV/AIDS prevention and care. In: International conference: "Health care for all", Antwerp, Belgium, 25-26 October 2001. [s.l.]: [s.n.], 2001: 11 pp.
  • Buvé A, Caraël M, Hayes RJ, Auvert B, Ferry B, Robinson NJ, Anagonou S, Kanhonou L, Laourou M, Abega S, Akam E, Zekeng L, Chege J, Kahindo M, Rutenberg N, Kaona F, Musonda R, Sukwa T, Morison L, Weiss HA, Laga M, Study Group on Heterogeneity of HIV Epidemics in African Cities. Multicentre study on factors determining differences in rate of spread of HIV in sub-Saharan Africa: methods and prevalence of HIV infection. AIDS 2001; 15(Suppl.4): S5-S14.
  • Buvé A, Caraël M, Hayes RJ, Auvert B, Ferry B, Robinson NJ, Anagonou S, Kanhonou L, Laourou M, Abega S, Akam E, Zekeng L, Chege J, Kahindo M, Rutenberg N, Kaona F, Musonda R, Sukwa T, Morison L, Weiss HA, Laga M, Study Group on Heterogeneity of HIV Epidemics in African Cities. The multicentre study on factors determining the differential spread of HIV in four African cities: summary and conclusions. AIDS 2001; 15(Suppl.4): S127-S131.
  • Buvé A, Changalucha J, Mayaud P, Gavyole A, Mugeye K, Todd J, Clayton T, Mosha F, Grosskurth H, Mabey D, Laga M, Van Lerberghe W, Hayes RJ. How many patients with a sexually transmitted infection are cured by health services? A study from Mwanza region, Tanzania. Trop Med Int Health 2001; 6: 971-979.
  • Buvé A, Lagarde E, Caraël M, Rutenberg N, Ferry B, Glynn JR, Laourou M, Akam E, Chege J, Sukwa T, Study Group on Heterogeneity of HIV Epidemics in African Cities. Interpreting sexual behaviour data: validity issues in the multicentre study on factors determining the differential spread of HIV in four African cities. AIDS 2001; 15(Suppl.4): S117-S126.
  • Buvé A, Weiss HA, Laga M, Van Dyck E, Musonda R, Zekeng L, Kahindo M, Anagonou S, Morison L, Robinson NJ, Hayes RJ, Study Group on Heterogeneity of HIV Epidemics in African Cities. The epidemiology of gonorrhoea, chlamydial infection and syphilis in four African cities. AIDS 2001; 15(Suppl.4): S79-S88.
  • Buvé A, Weiss HA, Laga M, Van Dyck E, Musonda R, Zekeng L, Kahindo M, Anagonou S, Morison L, Robinson NJ, Hayes RJ, Study Group on Heterogeneity of HIV Epidemics in African Cities. The epidemiology of trichomoniasis in women in four African cities. AIDS 2001; 15(Suppl.4): S89-S96.
  • Cardo D, Buvé A. Transmission of HIV in health care settings. In: Lamptey PR, Gayle HD, editors. HIV/AIDS prevention and care in resource-constrained settings; a handbook for the design and management of programs. Arlington: Family Health International (FHI), 2001: 501-516.
  • Chemlal K, De Ridder K, Fonteyne PA, Meyers WM, Swings J, Portaels F. The use of IS2404 restriction fragment length polymorphisms suggests the diversity of Mycobacterium ulcerans from different geographical areas. Am J Trop Med Hyg 2001; 64: 270-273.
  • Chemlal K, Huys G, Fonteyne PA, Vincent V, Lopez AG, Rigouts L, Swings J, Meyers WM, Portaels F. Evaluation of PCR-restriction profile analysis and IS2404 restriction fragment length polymorphism and amplified fragment length polymorphism fingerprinting for identification and typing of Mycobacterium ulcerans and M. marinum. J Clin Microbiol 2001; 39: 3272-3278.
  • Davis D, Trischmann H, Stephens DM, Lachmann PJ. Antibodies raised to short synthetic peptides with sequences derived from HIV-1SF2 gp120 can both neutralize and enhance HIV-1SF13: a later variant isolated from the same host. J Med Virol 2001; 64: 207-216.
  • De Baere T, Moerman M, Rigouts L, Dhooge C, Vermeersch H, Verschraegen G, Vaneechoutte M. Mycobacterium interjectum as causative agent of cervical lymphadenitis. J Clin Microbiol 2001; 39: 725-727.
  • Delvaux T, Buekens P, Godin I, Boutsen M. Barriers to prenatal care in Europe. Am J Prev Med 2001; 21: 52-59.
  • Delvaux T, Buvé A, Laga M. Inaccurate statements about sexually transmitted infections [letter]. Am J Obstet Gynecol 2001; 184: 1308.
  • Ernest I, Alexandre I, Zammatteo N, Herman M, Houbion A, De Leener F, Fransen K, van der Groen G, Remacle J. Quantitative assay for group M (subtype A-H) and group O HIV-1 RNA detection in plasma. J Virol Methods 2001; 93: 1-14.
  • Escutenaire S, Chalon P, Heyman P, Van der Auwera G, van der Groen G, Verhagen R, Thomas I, Karelle-Bui L, Vaheri A, Pastoret PP, Plyusnin A. Genetic characterization of Puumala hantavirus strains from Belgium: evidence for a distinct phylogenetic lineage. Virus Res 2001; 74: 1-15.
  • Ferry B, Caraël M, Buvé A, Auvert B, Laourou M, Kanhonou L, de Loenzien M, Akam E, Chege J, Kaona F, Study Group on Heterogeneity of HIV Epidemics in African Cities. Comparison of key parameters of sexual behaviour in four African urban populations with different levels of HIV infection. AIDS 2001; 15(Suppl.4): S41-S50.
  • Fransen K, Beelaert G, van der Groen G. Evaluation of four HIV antigen tests. J Virol Methods 2001; 93: 189-193.
  • Gallwey J, Crabbé F. STD program management and evaluation. In: Lamptey PR, Gayle HD, editors. HIV/AIDS prevention and care in resource-constrained settings; a handbook for the design and management of programs. Arlington: Family Health International (FHI), 2001: 381-406.
  • Ghys PD, Diallo MO, Ettiègne-Traoré V, Satten GA, Anoma CK, Maurice C, Kadjo JC, Coulibaly IM, Wiktor SZ, Greenberg AE, Laga M. Effect of interventions to control sexually transmitted disease on the incidence of HIV infection in female sex workers. AIDS 2001; 15: 1421-1431.
  • Glynn JR, Buvé A, Caraël M, Macauley IB, Kahindo M, Musonda RM, Zekeng L. Is long postpartum sexual abstinence a risk factor for HIV? [letter]. AIDS 2001; 15: 1059-1061.
  • Glynn JR, Buvé A, Carael M, Musonda RM, Kahindo M, Macauley I, Tembo F, Zekeng L. Factors influencing the difference in HIV prevalence between antenatal clinic and general population in sub-Saharan Africa. AIDS 2001; 15: 1717-1725.
  • Glynn JR, Caraël M, Auvert B, Kahindo M, Chege J, Musonda R, Kaona F, Buvé A, Study Group on Heterogeneity of HIV Epidemics in African Cities. Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia. AIDS 2001; 15(Suppl.4): S51-S60.
  • Goloubeva V, Lecocq M, Lassowsky P, Matthys F, Portaels F, Bastian I. Evaluation of mycobacteria growth indicator tube for direct and indirect drug susceptibility testing of Mycobacterium tuberculosis from respiratory specimens in a Siberian prison hospital. J Clin Microbiol 2001; 39: 1501.
  • Gomez A, Mve-Obiang A, Vray B, Rudnicka W, Shamputa IC, Portaels F, Meyers WM, Fonteyne PA, Realini L. Detection of phospholipase C in nontuberculous mycobacteria and its possible role in hemolytic activity. J Clin Microbiol 2001; 39: 1396-1401.
  • Grosskurth H, Mwijarubi E, Todd J, Rwakatare M, Orroth K, Mayaud P, Cleophas B, Buvé A, Mkanje R, Ndeki L, Gavyole A, Hayes R, Mabey D. Operational performance of and STD control programme in Mwanza Region, Tanzania. Sex Transm Infect 2000; 76: 426-436.
  • Ishikawa K, Janssens W, Banor JS, Shinno T, Piedade J, Sata T, Ampofo WK, Brandful JAM, Koyanagi Y, Yamamoto N, Canas-Ferreira WF, Adu-Sarkodie Y, Kurata T. Genetic analysis of HIV type 2 from Ghana and Guinea-Bissau, West Africa. AIDS Res Hum Retroviruses 2001; 17: 1661-1663.
  • Kazennova YV, Bobkov AF, Selimova LM, Khanina TA, Pokrovsky VV, Heyndrickx L, van der Groen G. [Analysis of gag gene subtypes of HIV-1 variants isolated in Russia by comparative assessment of heteroduplex electrophoretic mobility]. Vopr Virusol 2001; 46: 12-16.
  • Laga M, Schwärtlander B, Pisani E, Sow PS, Caraël M. To stem HIV in Africa, prevent transmission to young women. AIDS 2001; 15: 931-934.
  • Lagarde E, Auvert B, Caraël M, Laourou M, Ferry B, Akam E, Sukwa T, Morison L, Maury E, Chege J, N'Doye I, Buvé A, Study Group on Heterogeneity of HIV Epidemics in African Cities. Concurrent sexual partnerships and HIV prevalence in five urban communities of sub-Saharan Africa. AIDS 2001; 15: 877-884.
  • Lagarde E, Auvert B, Chege J, Sukwa T, Glynn JR, Weiss HA, Akam E, Laourou M, Caraël M, Buvé A, Study Group on Heterogeneity of HIV Epidemics in African Cities. Condom use and its association with HIV/sexually transmitted diseases in four urban communities of sub-Saharan Africa. AIDS 2001; 15(Suppl.4): S71-S78.
  • Lagarde E, Caraël M, Glynn JR, Kanhonou L, Abega SC, Kahindo M, Musonda R, Auvert B, Buvé A, Study Group on the Heterogeneity of HIV Epidemics in African Cities. Educational level is associated with condom use within non-spousal partnerships in four cities of sub-Saharan Africa. AIDS 2001; 15: 1399-1408.
  • Loseke NT, Kazadi KT, Kayembe KT, Portaels F, Mulumba MP. Problématique du diagnostic des neuropathies lépreuses en République Démocratique du Congo. Congo Méd 2001; 3: 354-358.
  • Mauck C, Rosenberg Z, Van Damme L, International Working Group on Microbicides. Recommendations for the clinical development of topical microbicides: an update. AIDS 2001; 15: 857-868.
  • Mayanja-Kizza H, Wajja A, Wu M, Peters P, Nalugwa G, Mubiru F, Aung H, Vanham G, Hirsch C, Whalen C, Ellner J, Toossi Z. Activation of beta-chemokines and CCR5 in persons infected with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis 2001; 183: 1801-1804.
  • Morison L, Buvé A, Zekeng L, Heyndrickx L, Anagonou S, Musonda R, Kahindo M, Weiss HA, Hayes RJ, Laga M, Janssens W, van der Groen G, Study Group on Heterogeneity of HIV Epidemics in African Cities. HIV-1 subtypes and HIV epidemics in four cities in sub-Saharan Africa. AIDS 2001; 15(Suppl.4): S109-S116.
  • Morison L, Weiss HA, Buvé A, Caraël M, Abega SC, Kaona F, Kanhonou L, Chege J, Hayes RJ, Study Group on Heterogeneity of HIV Epidemics in African Cities. Commercial sex and the spread of HIV in four cities in sub-Saharan Africa. AIDS 2001; 15(Suppl.4): S61-S69.
  • Mve-Obiang A. Etude de la cytotoxicité de Mycobacterium ulcerans: agent étiolo de l'ulcère de Buruli [dissertation]. Namur Anvers: Facultés Universitaires Notre Dame de la Paix, Laboratoire de Biologie et Biochimie Cellulaire Institut de Médecine Tropicale, Laboratoire de Mycobactériologie, 2001: 154 + div. pp.
  • Mve-Obiang A, Mestdagh M, Portaels F. DNA isolation from chloroform/methanol-treated mycobacterial cells without lysozyme and proteinase K. Biotechniques 2001; 30: 272-276.
  • Nkengasong JN, Kestens L, Ghys PD, Koblavi-Dème S, Bilé C, Kalou M, Ya KL, Traoré-Ettiegne V, Maurice C, Laga M, Wiktor SZ, Greenberg AE. Human immunodeficiency virus type 1 (HIV-1) plasma virus load and markers of immune activation among HIV-infected female sex workers with sexually transmitted diseases in Abidjan, Côte d'Ivoire. J Infect Dis 2001; 183: 1405-1408.
  • Ondoa P. Immunologic and virologic follow-up of 2 SIVcpz-infected chimpanzees: investigation of the mechanisms involved in resistance to disease progression [dissertation]. Antwerpen: Universiteit Antwerpen, Faculteit Medische and Farmaceutische Wetenschappen, Departement Geneeskunde, 2001: 197 pp.
  • Ondoa P, Davis D, Willems B, Heyndrickx L, Kestens L, van der Berg I, Coppens S, Janssens W, Heeney J, van der Groen G. Genetic variability of the V1 and V2 env domains of SIVcpz-ant and neutralization pattern of plasma viruses in a chimpanzee infected naturally. J Med Virol 2001; 65: 765-776.
  • Ondoa P, Kestens L, Davis D, Vereecken C, Willems B, Fransen K, Vingerhoets J, Zissis G, ten Haaft P, Heeney J, van der Groen G. Longitudinal comparison of virus load parameters and CD8 T-cell suppressive capacity in two SIVcpz-infected chimpanzees. J Med Primatol 2001; 30: 243-253.
  • Pfyffer GE, Strässle A, van Gorkum T, Portaels F, Rigouts L, Mathieu C, Mirzoyev F, Traore H, van Embden JDA. Multidrug-resistant tuberculosis in prison inmates, Azerbaijan. Emerg Infect Dis 2001; 7: 855-861.
  • Portaels F, Chemlal K, Elsen P, Johnson PDR, Hayman JA, Hibble J, Kirkwood R, Meyers WM. Mycobacterium ulcerans in wild animals. Rev Sci Tech Off Int Epizoot 2001; 20: 252-264.
  • Portaels F, Johnson P, Meyers WM, Eds. Buruli ulcer; diagnosis of Mycobacterium ulcerans disease; a manual for health care providers. Geneva: World Health Organisation (WHO), 2001: 92 pp. (WHO/CDS/CPE/GBUI/2001.4).
  • Rigouts L, Portaels F. New trends in the epidemiology of tuberculosis. In: Goossens H, Peetermans W, Struelens M, editors. Emerging bacterial pathogens; proceedings of the 2nd Elzenveld Workshop on Infectious Diseases, Antwerp, December 14-16, 2000. Waterloo: Bristol-Myers Squibb Belgium, 2001: 23-39.
  • Scott JT, Turner CMR, Mutapi F, Woolhouse MEJ, Ndhlovu PD, Hagan P. Cytokine responses to mitogen and Schistosoma haematobium antigens are different in children with distinct infection histories. Parasite Immunol 2001; 23: 519-526.
  • Stamatatos L, Davis D. New insights into protective humoral responses and HIV vaccines. AIDS 2001; 15(Suppl.5): S105-S115.
  • Suffys PN, da Silva Rocha A, de Oliveira M, Dias Campos CE, Werneck Barreto AM, Portaels F, Rigouts L, Wouters G, Jannes G, Van Reybroeck G, Mijs W, Vanderborght B. Rapid identification of mycobacteria to the species level using INNO-LiPA mycobacteria, a reverse hybridization assay. J Clin Microbiol 2001; 39: 4477-4482.
  • Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K. Protective efficacy of a DNA vaccine encoding antigen 85 A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun 2001; 69: 5403-5411.
  • Tekle-Michael T, Van Dyck E, Abdellati S, Laga M. Development of a heminested polymerase chain reaction assay for the detection of Haemophilus ducreyi in clinical specimens. Int J STD AIDS 2001; 12: 797-803.
  • ten Haaft P, Murthy K, Salas M, McClure H, Dubbes R, Koornstra W, Niphuis H, Davis D, van der Groen G, Heeney J. Differences in early virus loads with different phenotypic variants of HIV-1 and SIVcpz in chimpanzees. AIDS 2001; 15: 2085-2092.
  • Valet G, Kahle H, Otto F, Brautigam E, Kestens L. Prediction and precise diagnosis of diseases by data pattern analysis in multiparameter flow cytometry: melanoma, juvenile asthma, and human immunodeficiency virus infection. Methods Cell Biol 2001; 64: 487-508.
  • Van Deun A, Hamid Salim A, Rigouts L, Rahman M, Fissette K, Portaels F. Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases. Int J Tuberc Lung Dis 2001; 5: 329-338.
  • Van Deun A. In reply - more on periphery to centre quality control of sputum smear microscopy and 'rapid fading' of Ziehl-Neelsen staining [letter]. Int J Tuberc Lung Dis 2001; 5: 388-389.
  • Van der Auwera G, Janssens W, Heyndrickx L, van der Groen G. Reanalysis of full-length HIV type 1 group M subtype K and sub-subtype F2 with an MS-DOS bootscanning program. AIDS Res Hum Retroviruses 2001; 17: 185-189.
  • van der Groen G. The urgent need for feasibility studies of antiretroviral treatment in HIV-infected individuals in resource-limited settings [letter]. AIDS 2001; 15: 2342-2344.
  • Van Dyck E, Alary M, Guédou A, Abdellati S, Lafia E, Anagonou S. Antimicrobial susceptibilities and plasmid patterns of Neisseria gonorrhoeae. Int J STD AIDS 2001; 12: 89-93.
  • Van Dyck E, de Deken B, Laga M. Effect of adverse storage conditions of antigen reagent on performance of the rapid plasma reagin test. Int J STD AIDS 2001; 12: 299-301.
  • Van Dyck E, Ieven M, Pattyn S, Van Damme L, Laga M. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by enzyme immunoassay, culture, and three nucleic acid amplification tests. J Clin Microbiol 2001; 39: 1751-1756.
  • Van Dyck E, Karita E, Abdellati S, Van Hove D, Ngabonziza M, Lafort Y, Laga M. Antimicrobial susceptibilities of Neisseria gonorrhoeae in Kigali, Rwanda, and trends of resistance between 1986 and 2000. Sex Transm Dis 2001; 28: 539-545.
  • Van Dyck E, Meheus AZ, Piot P. Diagnó de laboratorio de las enfermedades de transmisión sexual. Ginebra: Organización Mundial de la Salud (OMS), 2000: 141 pp.
  • Van Dyck E, Smet H, Van Damme L, Laga M. Evaluation of the Roche Neisseria gonorrhoeae 16S rRNA PCR for confirmation of AMPLICOR PCR-positive samples and comparison of its diagnostic performance according to storage conditions and preparation of endocervical specimens. J Clin Microbiol 2001; 39: 2280-2282.
  • Van Vaerenbergh K, Debaisieux L, De Cabooter N, Declercq C, Desmet K, Fransen K, Maes B, Marissens D, Miller K, Muyldermans G, Sprecher S, Stuyver L, Vaira D, Verhofstede C, Zissis G, Van Ranst M, De Clercq E, Desmyter J, Vandamme AM. Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1 infected patients in Belgium. Antiviral Ther 2001; 6: 63-70.
  • Vuylsteke B, Ghys PD, Mah-bi G, Konan Y, Traoré M, Wiktor SZ, Laga M. Where do sex workers go for health care? A community based study in Abidjan, Côte d'Ivoire. Sex Transm Infect 2001; 77: 351-352.
  • Vuylsteke B, Jana S. Reducing HIV risk in sex workers, their clients and partners. In: Lamptey PR, Gayle HD, editors. HIV/AIDS prevention and care in resource-constrained settings; a handbook for the design and management of programs. Arlington: Family Health International (FHI), 2001: 187-210.
  • Weiss HA, Buvé A, Robinson NJ, Van Dyck E, Kahindo M, Anagonou S, Musonda R, Zekeng L, Morison L, Caraël M, Laga M, Hayes RJ, Study Group on Heterogeneity of HIV Epidemics in African Cities. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS 2001; 15(Suppl.4): S97-S108.
 

2000

  • Abalos FMV, Aguiar J, Guédénon A, Portaels F, Meyers WM. Mycobacterium ulcerans infection (Buruli ulcer); a case report of the disseminated nonulcerative form. Ann Diagn Pathol 2000; 4: 386-390.
  • Aerts A, Habouzit M, Mschiladze L, Malakmadze N, Sadradze N, Menteshashvili O, Portaels F, Sudre P. Pulmonary tuberculosis in prisons of the ex-USSR state Georgia: results of a nation-wide prevalence survey among sentenced inmates. Int J Tuberc Lung Dis 2000; 4: 1104-1110.
  • Asiedu K, Portaels F. Introduction. In: Asiedu K, Scherpbier R, Raviglione M, editors. Buruli ulcer, Mycobacterium ulcerans infection. Geneva: World Health Organization (WHO), Global Buruli Ulcer Initiative, 2000: 5-7. (WHO/CDS/CPE/GBUI/2000.1).
  • Aujoulat I, Zinsou C, Johnson C, Guédénon A, Portaels F. Prise en charge précoce des cas d'ulcère de Buruli: le poids des croyances et des représentations. Bull ALLF 2000; 7: 35-37.
  • Bastian I, Portaels F, editors. Multidrug-resistant tuberculosis. Dordrecht: Kluwer, 2000: 312 pp. (Resurgent and Emerging Infectious Diseases; 1)
  • Bastian I, Portaels F. Introduction: multidrug-resistant tuberculosis: past, present and future. In: Bastian I, Portaels F, editors. Multidrug-resistant tuberculosis. Dordrecht: Kluwer, 2000: 1-15. (Resurgent and Emerging Infectious Diseases; 1)
  • Bastian I, Rigouts L, Van Deun A, Portaels F. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required? Bull World Health Organ 2000; 78: 238-251.
  • Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunders R, Janssens W, van der Groen G. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol 2000; 61: 14-24.
  • Bonard D, Msellati P, Rigouts L, Combe P, Coulibaly D, Coulibaly IM, Portaels F. What is the meaning of repeated isolation of Mycobacterium africanum? Int J Tuberc Lung Dis 2000; 4: 1176-1180.
  • Bone A, Aerts A, Grzemska M, Kimerling M, Kluge H, Levy M, Portaels F, Raviglione M, Varaine F. Tuberculosis control in prisons; a manual for programme managers. Geneva: World Health Organization (WHO), 2000: 191 pp. (WHO/CDS/TB/2000.281).
  • Borchert M, Boelaert M, Sleurs H, Muyembe-Tamfum JJ, Pirard P, Colebunders R, Van der Stuyft P, van der Groen G. Viewpoint: filovirus haemorrhagic fever outbreaks: much ado about nothing? Trop Med Int Health 2000; 5: 318-324.
  • Buvé A. STD control as a component of HIV control strategies. In: Carosi G, Fiallo P, Matteelli A, Nunzi E, editors. Sexually transmitted diseases in the tropics. Bologna: Associazione Italiana "Amici di R. Follereau" (AIFO), 2000: 125-131. (Nunzi E, Ed. Quaderni di Cooperazione Sanitaria. Health Co-Operation Papers. Cahiers de Cooperation Médicale; 16).
  • Buvé A, Laga M, Remes P, Padian N, Morison L. Ethics of mass STD treatment [letter]. Lancet 2000; 356: 1115-1116.
  • Cham F, Heyndrickx L, Janssens W, Van der Auwera G, Vereecken K, De Houwer K, Coppens S, Whittle H, van der Groen G. Study of HIV type 1 gag/env variability in The Gambia, using a multiplex DNA polymerase chain reaction. AIDS Res Hum Retroviruses 2000; 17: 1915-1919.
  • Cham F, Heyndrickx L, Janssens W, Vereecken K, De Houwer K, Coppens S, Van der Auwera G, Whittle H, van der Groen G. Development of a one-tube multiplex reverse transcriptase-polymerase chain reaction assay for the simultaneous amplification of HIV type 1 group M gag and env heteroduplex mobility assay fragments. AIDS Res Hum Retroviruses 2000; 16: 1503-1505.
  • Colebunders R, Bastian I. A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 97-107.
  • Colebunders R, Fransen K, Florence E, Vanham G. HIV-1 viral load and scrub typhus [letter]. Lancet 2000; 356: 1765-1766.
  • Crabbé F, Vuylsteke B, De Clerck M, Laga M. Cost-effectiveness of management strategies for acute urethritis in the developing world. Trop Med Int Health 2000; 5: 640-647.
  • Crofton J, Van Deun A. Treatment of multidrug-resistant tuberculosis in developing countries. In: Bastian I, Portaels F, editors. Multidrug-resistant tuberculosis. Dordrecht: Kluwer, 2000: 191-203. (Resurgent and Emerging Infectious Diseases; 1)
  • Dasse R, Soumare M, Akre DP, Seka SJ, Siransy Bogui L, Sombo MF, Kestens L. Etude de l'expression du CD27 sur les lymphocytes TCD4+ dans l'infection par le VIH. Méd Afrique Noire 2000; 47: 319-321.
  • De Baar MP, Janssens W, De Ronde A, Fransen K, Colebunders R, Kestens L, van der Groen G, Goudsmit J. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo. AIDS Res Hum Retroviruses 2000; 16: 1385-1394.
  • Faber WR, Pereira Arias-Bouda LM, Zeegelaar JE, Kolk AHJ, Fonteyne PA, Toonstra J, Portaels F. First reported case of Mycobacterium ulcerans infection from China. Trans R Soc Trop Med Hyg 2000; 94: 277-279.
  • Gaspar MM, Neves S, Portaels F, Pedrosa J, Silva MT, Cruz ME. Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection. Antimicrob Agents Chemother 2000; 44: 2424-2430.
  • Ghys PD, Bélec L, Diallo MO, Ettiègne-Traoré V, Becquart P, Maurice C, Nkengasong JN, Coulibaly IM, Greenberg AE, Laga M, Wiktor SZ. Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Côte d'Ivoire. AIDS 2000; 14: 2603-2608.
  • Gomez A, Mve-Obiang A, Vray B, Remacle J, Chemlal K, Meyers WM, Portaels F, Fonteyne PA. Biochemical and genetic evidence for phospholipase C activity in Mycobacterium ulcerans. Infect Immun 2000; 68: 2995-2997.
  • Gómez-López A. Phospholipase C and hemolysis in nontuberculous mycobacteria [dissertation]. Brussels: Free University of Brussels, Faculty of Medicine, Experimental Immunology Laboratory, 2000: 114+div pp.
  • Guédénon A, Portaels F. Cartographie de l'ulcère de Buruli au Bénin. Bruxelles: DGIS/DGCI, 2000: 21 pp.
  • Guédenon A, Portaels F. Ulcère de Buruli (infection à Mycobacterium ulcerans); guide diagnostique à l'usage des professionnels de la santé. [s.l.]: [s.n.], 2000: 46 pp.
  • Hertoghe T, Wajja A, Ntambi L, Okwera A, Aziz MA, Hirsch C, Johnson J, Toossi Z, Mugerwa R, Mugyenyi P, Colebunders R, Ellner J, Vanham G. T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). Clin Exp Immunol 2000; 122: 350-357.
  • Heyndrickx L, Janssens W, Ndumbe PM, Vereecken K, Coppens S, De Houwer K, Fransen K, Van der Auwera G, van der Groen G. HIV-1 genetic variability in Cameroon [letter]. AIDS 2000; 14: 1862-1864.
  • Heyndrickx L, Janssens W, Zekeng L, Musonda R, Anagonou S, Van der Auwera G, Coppens S, Vereecken K, De Witte K, Van Rampelbergh R, Kahindo M, Morison L, McCutchan FE, Carr JK, Albert J, Essex M, Goudsmit J, Asjö B, Salminen M, Buvé A & Study Group on Heterogeneity of HIV Epidemics in African Cities. Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. J Virol 2000; 74: 363-370.
  • Huys G, Rigouts L, Chemlal K, Portaels F, Swings J. Evaluation of amplified fragment length polymorphism analysis for inter- and intraspecific differentiation of Mycobacterium bovis, M. tuberculosis, and M. ulcerans. J Clin Microbiol 2000; 38: 3675-3680.
  • Janssens W, Laukkanen T, Salminen MO, Carr JK, Van der Auwera G, Heyndrickx L, van der Groen G, McCutchan FE. HIV-1 subtype H near-full length genome reference strains and analysis of subtype-H-containing inter-subtype recombinants. AIDS 2000; 14: 1533-1543.
  • Janssens W, Salminen MO, Laukkanen T, Heyndrickx L, Van der Auwera G, Colebunders R, McCutchan FE, van der Groen G. Near full-length genome analysis of HIV type 1 CRF02.AG subtype C and CRF02.AG subtype G recombinants. AIDS Res Hum Retroviruses 2000; 16: 1183-1189.
  • Jennes W, Dicks LM, Verwoerd DJ. Enterocin 012, a bacteriocin produced by Enterococcus gallinarum isolated from the intestinal tract of ostrich. J Appl Microbiol 2000; 88: 349-357.
  • Johnson P, Stinear T, Portaels F, Chamal K, Dobos K, King H. Modern diagnostic techniques. In: Asiedu K, Scherpbier R, Raviglione M, editors. Buruli ulcer, Mycobacterium ulcerans infection. Geneva: World Health Organization (WHO), Global Buruli Ulcer Initiative, 2000: 23-30. (WHO/CDS/CPE/GBUI/2000.1).
  • Johnson P, Stinear T, Portaels F, Chamal K, Dobos K, King H. Techniques modernes de diagnostic. In: Asiedu K, Scherpbier R, Raviglione M, editors. Ulcère de Buruli, infection à Mycobacterium ulcerans. Geneva: World Health Organization (WHO), 2000: 21-29. (WHO/CDS/CPE/GBUI/2000.1).
  • Lagarrigue V, Portaels F, Abalos F, Meyers WM, Aguiar J. L'ulcère de Buruli; attention aux atteintes osseuses. Bull ALLF 2000; 6: 33-34.
  • Lagarrigue V, Portaels F, Meyers WM, Aguiar J. L'ulcère de Buruli: attention aux atteintes osseuses! A propos de 33 cas observés au Bénin. Méd Trop 2000; 60: 262-266.
  • Laukkanen T, Carr JK, Janssens W, Liitsola K, Gotte D, McCutchan FE, Op de Coul E, Cornelissen M, Heyndrickx L, van der Groen G, Salminen MO. Virtually full-length subtype F and F/D recombinant HIV-1 from Africa and South America. Virology 2000; 269: 95-104.
  • Masciotra S, Rudolph DL, van der Groen G, Yang C, Lal RB. Serological detection of infection with diverse human and simian immunodeficiency viruses using consensus env peptides. Clin Diagn Lab Immunol 2000; 7: 706-709.
  • Mestdagh M, Realini L, Fonteyne PA, Rossau R, Jannes G, Mijs W, De Smet KAL, Portaels F, Van den Eeckhout E. Correlation of pncA sequences with pyrazinamide resistance level in BACTECtm for 21 Mycobacterium tuberculosis clinical isolates. Microb Drug Resist 2000; 6: 283-288.
  • Mooij P, Bogers WM, Oostermeijer H, Koornstra W, ten Haaft PJ, Verstrepen BE, Van der Auwera G, Heeney JL. Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. J Virol 2000; 74: 4017-4027.
  • Mukenge-Tshibaka L, Alary M, Bernier F, Van Dyck E, Lowndes CM, Gu‚dou A, Anagonou S, Joly JR. Diagnostic performance of the Roche AMPLICOR PCR in detecting Neisseria gonorrhoeae in genitourinary specimens from female sex workers in Cotonou, Benin. J Clin Microbiol 2000; 38: 4076-4079.
  • Muyldermans G, Debaisieux L, Fransen K, Marissens D, Miller K, Vaira D, Vandamme AM, Vandenbroucke AT, Verhofstede C, Schuurman R, Zissis G, Lauwers S. Blinded, multicenter quality control study for the quantification of human immunodeficiency virus type 1 RNA in plasma by the Belgian AIDS reference laboratories. Clin Microbiol Infect 2000; 6: 213-217.
  • Nkengasong JN, Kestens L, Ghys PD, Koblavi-Dème S, Otten RA, Bilé C, Maurice C, Kalou M, Laga M, Wiktor SZ, Greenberg AE. Dual infection with human immunodeficiency virus type 1 and type 2: impact on HIV type 1 viral load and immune activation markers in HIV-seropositive female sex workers in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses 2000; 16: 1371-1378.
  • Op de Coul E, Van der Schoot A, Goudsmit J, Van den Burg R, Janssens W, Heyndrickx L, van der Groen G, Cornelissen M. Independent introduction of transmissible F/D recombinant HIV-1 from Africa into Belgium and The Netherlands. Virology 2000; 270: 267-277.
  • Palomino JC. Novel rapid antimicrobial susceptibility tests for Mycobacterium tuberculosis. In: Bastian I, Portaels F, editors. Multidrug-resistant tuberculosis. Dordrecht: Kluwer, 2000: 145-162. (Resurgent and Emerging Infectious Diseases; 1)
  • Palomino JC, Portaels F. Microcolony detection for rapid diagnosis of Mycobacterium tuberculosis infection [letter]. Int J Tuberc Lung Dis 2000; 4: 91.
  • Pattyn SR. Monkeypoxvirus infections. Rev Sci Tech Off Int Epizoot 2000; 19: 92-97.
  • Pattyn SR. Pour vivre heureux, vivons cachés (J.P. Claris de Florian); de kennis van de virusreservoirs is essentieel bij de bestrijding van infectieziekten. Verh K Acad Geneeskd Belg 2000; 62: 1-13.
  • Pattyn S, Grillone S. A 6 week quadruple drug regimen for the treatment of multibacillary leprosy. Lepr Rev 2000; 71: 43-46.
  • Pelgrom J, Bastian I, Van den Enden E, Portaels F, Colebunders R. Cutaneous ulcer caused by Mycobacterium avium and recurrent genital herpes after highly active antiretroviral therapy [letter]. Arch Dermatol 2000; 136: 129.
  • Portaels F. Basic microbiology. In: Asiedu K, Scherpbier R, Raviglione M, editors. Buruli ulcer, Mycobacterium ulcerans infection. Geneva: World Health Organization (WHO), Global Buruli Ulcer Initiative, 2000: 15-17. (WHO/CDS/CPE/GBUI/2000.1).
  • Portaels F. Microbiologie fondamentale. In: Asiedu K, Scherpbier R, Raviglione M, editors. Ulcère de Buruli, infection à Mycobacterium ulcerans. Geneva: World Health Organization (WHO), 2000: 13-15. (WHO/CDS/CPE/GBUI/2000.1).
  • Quiñones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, Vanham G, van der Groen G, Colebunders RL, Arts EJ. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 2000; 74: 9222-9233.
  • Ramjee G, Morar NS, Alary M, Mukenge-Tshibaka L, Vuylsteke B, Ettiègne-Traoré V, Chandeying V, Karim SA, Van Damme L. Challenges in the conduct of vaginal microbicide effectiveness trials in the developing world. AIDS 2000; 14: 2553-2557.
  • Rigouts L. Use of molecular tools for the control of human and bovine tuberculosis [dissertation]. Gent: Universiteit Gent, Vakgroep Biochemie, Fysiologie en Microbiologie, 2000: 167 pp.
  • Sasse A, Liesnard C, van der Groen G, Burtonboy G, Plum J, Sondag-Thull D, Sprecher S, van Ranst M, Zissis G, Desmyter J. Recent increase in diagnoses of HIV infections based on surveillance system data in Belgium [letter]. AIDS 2000; 14: 2798-2780.
  • Steen R, Vuylsteke B, DeCoito T, Ralepeli S, Fehler G, Conley J, Bruckers L, Dallabetta G, Ballard R. Evidence of declining STD prevalence in a South African mining community following a core-group intervention. Sex Transm Dis 2000; 27: 1-8.
  • Stinear T, Davies JK, Jenkin GA, Portaels F, Ross BC, Oppedisano F, Purcell M, Hayman JA, Johnson PDR. A simple PCR method for rapid genotype analysis of Mycobacterium ulcerans. J Clin Microbiol 2000; 38: 1482-1487.
  • Suffys P, Palomino JC, Cardoso Leao S, Espitia C, Cataldi A, Alito A, Velasco M, Robledo J, Fernandez J, da Silva Rosa P, Romano MI. Evaluation of the polymerase chain reaction for the detection of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2000; 4: 179-183.
  • Sumartojo E, Laga M. Structural factors in HIV prevention. AIDS 2000; 14(Suppl.1): S1-S73.
  • Thangaraj HS, Adjei O, Allen BW, Portaels F, Evans MRW, Banerjee DK, Wansbrough-Jones MH. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans. J Antimicrob Chemother 2000; 45: 231-233.
  • Traoré H, Fissette K, Bastian I, Devleeshouwer M, Portaels F. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator for multidrug resistance. Int J Tuberc Lung Dis 2000; 4: 481-484.
  • Van Bockstaele DR, Nijs G, Lenjou M, Bosmans E, Vanham G, Rodrigus I, Berneman ZN. GP130 and c-kit signaling, initiated by the sIL-6R/IL-6 complex, is sufficient to expand the primitive adult bone marrow CD34+CD38- pre-CFU cell. Ann Hematol 2000; 79: 667-671.
  • Van Damme L. Clinical research with topical microbicides as a potential HIV prevention method. AIDS Reader 2000; 10: 552-554.
  • Van Damme L, Chandeying V, Ramjee G, Rees H, Sirivongrangson P, Laga M, Perriëns J, COL-1492 Phase II Study Group. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. AIDS 2000; 14: 85-88.
  • Van Damme L, Wright A, Depraetere K, Rosenstein I, Vandersmissen V, Poulter L, McKinlay M, Van Dyck E, Weber J, Profy A, Laga M, Kitchen V. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm Infect 2000; 76: 126-130.
  • Van den Ende J, Van Gompel A, Van den Enden E, Taelman H, Vanham G, Vervoort T. Hyperreactive malaria in expatriates returning from sub-Saharan Africa. Trop Med Int Health 2000; 5: 607-611.
  • Van Deun A. Periphery to centre quality control of sputum smear microscopy and 'rapid fading' of Ziehl-Neelsen staining [reply]. Int J Tuberc Lung Dis 2000; 4: 888-889.
  • Van Deun A, Aung Kya Maug, Cooreman E, Hossain MA, Chambuganj N, Rema V, Marandi H, Kawria A, Portaels F. Bleach sedimentation method for increased sensitivity of sputum smear microscopy: does it work? Int J Tuberc Lung Dis 2000; 4: 371-376.
  • Van Dyck E. The STD laboratory. In: Carosi G, Fiallo P, Matteelli A, Nunzi E, editors. Sexually diseases in the tropics. Bologna: Associazione Italiana "Amici di R. Follereau" (AIFO), 2000: 159-183. (Nunzi E, Ed. Quaderni di Cooperazione Sanitaria. Health Co-Operation Papers. Cahiers de Cooperation Médicale; 16)
  • Van Dyck E, Meheus AZ, Piot P. Diagnostic au laboratoire des maladies sexuellement transmissibles. Genève: Organisation Mondiale de la Santé (OMS), 2000: 143 pp.
  • Vanham G, Davis D, Willems B, Penne L, Kestens L, Janssens W, van der Groen G. Dendritic cells, exposed to primary, mixed phenotype HIV-1 isolates preferentially, but not exclusively, replicate CCR5-using clones [letter]. AIDS 2000; 14: 1874-1876.
  • Vanham G, Penne L, Allemeersch H, Kestens L, Willems B, van der Groen G, Jeang KT, Toossi Z, Rich E. Modeling HIV transfer between dendritic cells and T cells: importance of HIV phenotype, dendritic cell-T cell contact and T-cell activation. AIDS 2000; 14: 2299-2311.
  • Vanham G, Penne L, Fransen K, Kestens L, De Brabander M. HIV-associated dysfunction of in vitro IL-12 production depends on the nature of the stimulus and on the CD4 T-cell count of the patient [letter]. Blood 2000; 95: 2185-2187.
  • Vanham G, Van Tendeloo V, Willems B, Penne L, Kestens L, Beirnaert E, Fransen K, Heyndrickx L, Zhong P, Davis D, Berneman Z, van der Groen G, Van Bockstaele D. The HIV-2 genotype and the HIV-1 syncytium-inducing phenotype are associated with a lower virus replication in dendritic cells. J Med Virol 2000; 60: 300-312.
  • Watson-Jones D, Mugeye K, Mayaud P, Ndeki L, Todd J, Mosha F, West B, Cleophas-Frisch B, Grosskurth H, Laga M, Hayes R, Mabey D, Buvé A. High prevalence of trichomoniasis in rural men in Mwanza, Tanzania: results from a population based study. Sex Transm Infect 2000; 76: 355-362.
  • Yang C, Dash BC, Simon F, van der Groen G, Pieniazek D, Gao F, Hahn BH, Lal RB. Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic pol and env primer pairs. J Infect Dis 2000; 181: 1791-1795.
  • Yang C, Gao F, Fonjungo PN, Zekeng L, van der Groen G, Pieniazek D, Schable C, Lal RB. Phylogenetic analysis of protease and transmembrane region of HIV type 1 group O. AIDS Res Hum Retroviruses 2000; 16: 1075-1081.
 

1999

  • Bastian I, Colebunders R. Treatment and prevention of multidrug-resistant tuberculosis. Drugs 1999; 58: 633-661.
  • Breman JG, Johnson KM, van der Groen G, Robbins CB, Szczeniowski MV, Ruti K, Webb PA, Meier F, Heymann DL. A search for Ebola virus in animals in the Democratic Republic of the Congo and Cameroon: ecologic, virologic, and serologic surveys, 1979-1980. J Infect Dis 1999; 179(Suppl.1): S139-S147.
  • Buvé A. Genital ulcer disease in Africa: many pieces are still missing from the puzzle [editorial]. Sex Transm Infect 1999; 75: 85-86.
  • Crabbé F, Laga M, Piot P. Human immunodeficiency virus and AIDS; epidemiology and prevention. In: Root RK, editor. Clinical infectious diseases; a practical approach. New York: Oxford University Press, 1999: 905-913.
  • Glynn JR, Buvé A, Caraël M, Zaba B. Adjustment of antenatal clinic HIV surveillance data for HIV-associated differences in fertility. AIDS 1999; 13: 1598-1599.
  • Guimaraes-Peres A, Portaels F, de Rijk P, Fisette K, Pattyn SR, Van Vooren JP, Fonteyne PA. Comparison of two PCRs for detection of Mycobacterium ulcerans. J Clin Microbiol 1999; 37: 206-208.
  • Heeney J, Akerblom L, Barnett S, Bogers W, Davis D, Fuller D, Koopman G, Lehner T, Mooij P, Morein B, De Giuli-Morghen C, Rosenwirth B, Verschoor E, Wagner R, Wolf H. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunol Lett 1999; 66: 189-195.
  • Hirsch CS, Toossi Z, Vanham G, Johnson JL, Peters P, Okwera A, Mugerwa R, Mugyenyi P, Ellner JJ. Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. J Infect Dis 1999; 179: 945-953.
  • Hu DJ, Buvé A, Baggs J, van der Groen G, Dondero TJ. What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective. AIDS 1999; 13: 873-881.
  • Janssens W, Heyndrickx L, Van der Auwera G, Nkengasong J, Beirnaert E, Vereecken K, Coppens S, Willems B, Fransen K, Peeters M, Ndumbe P, Delaporte E, van der Groen G. Interpatient genetic variability of HIV-1 group O. AIDS 1999; 13: 41-48.
  • Janssens W, Nkengasong J, Heyndrickx L, Van der Auwera G, Vereecken K, Coppens S, Willems B, Beirnaert E, Fransen K, Peeters M, van der Groen G. Intrapatient variability of HIV type 1 group O ANT70 during a 10-year follow-up. AIDS Res Hum Retroviruses 1999; 15: 1325-1332.
  • Kamali A, Nunn AJ, Mulder DW, Van Dyck E, Dobbins JG, Whitworth JAG. Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. Sex Transm Infect 1999; 75: 98-102.
  • Kimerling ME, Kluge H, Vezhnina N, Iacovazzi T, Demeulenaere T, Portaels F, Matthys F. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 1999; 3: 451-453.
  • McCutchan FE, Carr JK, Bajani M, Sanders-Buell E, Harry TO, Stoeckli TC, Robbins KE, Gashau W, Nasidi A, Janssens W, Kalish ML. Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. Virology 1999; 254: 226-234.
  • Mestdagh M, Fonteyne PA, Realini L, Rossau R, Jannes G, Mijs W, De Smet KAL, Portaels F, Van den Eeckhout E. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43: 2317-2319.
  • Meyers WM, Horsburgh CR, Portaels F. Buruli ulcer; review of a reemerging mycobacterial disease. In: Strecker W, Kinzl L, editors. Tropenchirurgie III. Tropical surgery III. Berlin: Springer Verlag, 1999: 262-271.
  • Meyers WM, Portaels F. Buruli ulcer (Mycobacterium ulcerans infection). Jap J Lepr 1999; 68: 23-27.
  • Mve-Obiang A, Remacle J, Palomino JC, Houbion A, Portaels F. Growth and cytotoxic activity by Mycobacterium ulcerans in protein-free media. FEMS Microbiol Lett 1999; 181: 153-157.
  • Nicoll A, Johnson AM, Adler MW, Laga M. Preventing HIV-1: lessons from Mwanza and Rakai [letter]. Lancet 1999; 353: 1522.
  • Padian N, Buvé A. Epidemiology [editorial]. AIDS 1999; 13(Suppl.A): S59-S60.
  • Palomino JC, Portaels F. Simple procedure for drug susceptibility testing of Mycobacterium tuberculosis using a commercial colorimetric assay. Eur J Clin Microbiol Infect Dis 1999; 18: 380-383.
  • Palomino JC, Traoré H, Fissette K, Portaels F. Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 1999; 3: 344-348.
  • Pattyn SR. Rechutes très tardives après traitement des maladies multibacillaires. Bull ALLF 1999; (5): 28.
  • Pattyn SR. Yersinia pestis, bacteriologie. Verh K Acad Geneeskd België 1999; 61: 103-107.
  • Ping Z, Guizheng L, Wei Z, Fransen K, Heyndrickx L, Janssens W, van der Groen G. Genotyping of HIV-1 in anti-HIV-1 sero-positive plasma. Virol Sin 1999; 14: 17-22.
  • Piper MA, Severin ST, Wiktor SZ, Unger ER, Ghys PD, Miller DL, Horowitz IR, Greenberg AE, Reeves WC, Vernon SD. Association of human papillomavirus with HIV and CD4 cell count in women with high or low numbers of sex partners. Sex Transm Infect 1999; 75: 253-257.
  • Portaels F, Elsen P, Guimaraes-Peres A, Fonteyne PA, Meyers WM. Insects in the transmission of Mycobacterium ulcerans infection [letter]. Lancet 1999; 353: 986.
  • Portaels F, Rigouts L, Bastian I. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Int J Tuberc Lung Dis 1999; 3: 582-588.
  • Realini L, De Ridder R, Hirschel B, Portaels F. Blood and charcoal added to acidified agar media promote the growth of Mycobacterium genavense. Diagn Microbiol Infect Dis 1999; 34: 45-50.
  • Rudnicka W, Brzychcy M, KLink M, Lopez AG, Fonteyne PA, Rusch-Gerdes S, Rozalska B. The production of nitric oxide and tumor necrosis factor by murine macrophages infected with mycobacterial strains differing by hemolytic activity. Microbiol Immunol 1999; 43: 637-644.
  • Rustomjee R, Abdool Karim Q, Abdool Karim SS, Laga M, Stein Z. Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. AIDS 1999; 13: 1511-1515.
  • Traore H. Analyse génétique des mécanismes de résistance à la rifampicine et de l transmission des souches du complexe Mycobacterium tuberculosis [dissertation]. Bruxelles: Université Libre de Bruxelles, Institut de Pharmacie, Laboratoire de Microbiologie et d'Hygiène, 1999: 209 pp.
  • Tsegaye TM. Potentials of a Haemophilus ducreyi-specific antigen and a monoclonal antibody for the laboratory diagnosis of chancroid [dissertation]. [Brussel]: Vrije Universiteit Brussel, Faculty of Science, Institute of Molecular Biology and Biotechnology, 1999: 131 pp.
  • Van Bockstaele DR, Deneys V, Philippé J, Bernier M, Kestens L, Chatelain B, De Waele M, Demanet C. Belgian consensus recommendations for flow cytometric immunophenotyping. Acta Clin Belg 1999; 54: 88-98.
  • Van Damme L, Laga M. Pointer: ethical and technical aspects of microbicide effectiveness trials. Int Antivir News 1999; 7(3).
  • Van Damme L, Rosenberg ZF. Microbicides and barrier methods in HIV prevention. AIDS 1999; 13(Suppl.A): S85-S92.
  • van der Groen G. Ebola en Marburg; dodelijk maar weinig gevaarlijk. Natuur & Techniek 1999; 67(12): 62-69.
  • Van Deun A, Aung KJM, Chowdhury S, Saha S, Pankaj A, Ashraf A, Rigouts L, Fissette K, Portaels F. Drug susceptibility of Mycobacterium tuberculosis in a rural area of Bangladesh and its relevance to the national treatment regimens. Int J Tuberc Lung Dis 1999; 3: 143-148.
  • Van Dyck E, Meheus AZ, Piot P. Laboratory diagnosis of sexually transmitted diseases. Geneva: World Health Organization (WHO), 1999: 135 pp.
  • Vanham G, Penne L, Devalck J, Kestens L, Colebunders R, Bosmans E, Thielemans K, Ceuppens JL. Decreased CD40 ligand induction in CD4 T cells and dysregulated IL-12 production during HIV infection. Clin Exp Immunol 1999; 117: 335-342.
  • Vernon SD, Unger ER, Piper MA, Severin ST, Wiktor SZ, Ghys PD, Miller DL, Horowitz IR, Greenberg AE, Reeves WC. HIV and human papillomavirus as independent risk factors for cervical neoplasia in women with high or low numbers of sex partners. Sex Transm Infect 1999; 75: 258-260.
  • Verschoor EJ, Davis D, van Gils M, Koopman G, Mooij P, Oostermeijer H, Haaft PT, Verstrepen B, Rosenwirth B, Morein B, Barnett SW, Heeney JL. Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus. J Med Primatol 1999; 28: 224-232.
  • Vuylsteke B, Laga M. Approach to management of STDs in developing countries. In: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WF, Piot P, Wasserheit JN, editors. Sexually transmitted diseases; 3rd ed. New York: McGraw-Hill, 1999: 1399-1408.
  • Vuylsteke B, Vandenbruaene M, Vandenbulcke P, Van Dyck E, Laga M. Chlamydia trachomatis prevalence and sexual behaviour among female adolescents in Belgium. Sex Transm Infect 1999; 75: 152-155.
  • Yang C, Pieniazek D, Owen SM, Fridlund C, Nkengasong J, Mastro TD, Rayfield MA, Downing R, Biryawaho B, Tanuri A, Zekeng L, van der Groen G, Gao F, Lal RB. Detection of phylogenetically diverse human immunodeficiency virus type 1 groups M and O from plasma by using highly sensitive and specific generic primers. J Clin Microbiol 1999; 37: 2581-2586.

 

   

1998

  • Alary M, Baganizi E, Guèdèmè A, Padonou F, Davo N, Adjovi C, Van Dyck E, Germain M, Joly J, Mahony JB. Evaluation of clinical algorithms for the diagnosis of gonococcal and chlamydial infections among men with urethral discharge or dysuria and women with vaginal discharge in Benin. Sex Transm Infect 1998; 74(Suppl.1): S44-S49.
  • Bär W, Rüsch-Gerdes S, Richter E, Marquéz de Bär G, Dittmer C, Papsdorf H, Stosiek P, de Rijk PB, Meyers WM, Portaels F. Mycobacterium ulcerans infection in a child from Angola: diagnosis by direct detection and culture. Trop Med Int Health 1998; 3: 189-196.
  • Balzarine J, Naesens L, Verbeken E, Laga M, Van Damme L, Parniak M, Van Mellaert L, Anné J, De Clercq E. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 1998; 12: 1129-1138.
  • Beirnaert E, Willems B, Peeters M, Bouckaert A, Heyndrickx L, Zhong P, Vereecken K, Coppens S, Davis D, Ndumbe P, Janssens W, van der Groen G. Design and evaluation of an in-house HIV-1 (group M and O) SIVmnd and SIVcpz antigen capture assay. J Virol Methods 1998; 73: 65-70.
  • Bogaerts J, Kestens L, Van Dyck E, Tello WM, Akingeneye J, Mukantabana V. Genital ulcers in a primary health clinic in Rwanda: impact of HIV infection on diagnosis and ulcer healing (1986-1992). Int J STD AIDS 1998; 9: 706-710.
  • Bogaerts J, Van Dyck E, Mukantabana B, Munyabikali JP, Martinez Tello W. Auxotypes, serovars, and trends of antimicrobial resistance of Neisseria gonorrhoeae in Kigali, Rwanda (1985-93). Sex Transm Infect 1998; 74: 205-209.
  • Brandful JAM, Ampofo WK, Janssens W, Adu-Sarkodie Y, Apeagyei F, Anyomi F, Aidoo S, Yamamoto N, Ishikawa K, Sata T, Kurata T. Genetic and phylogenetic analysis of HIV type 1 strains from southern Ghana. AIDS Res Hum Retroviruses 1998; 14: 815-819.
  • Buvé A. Le dialogue entre chercheurs verticalistes et horizontalistes en pratique: la recherche sur les maladies sexuellement transmissibles à Mwanza. In: Van Lerberghe W, de Béthune X, editors. Intégrations et recherche. Antwerpen: ITGPress, 1998: 71-80. (Studies in Health Services Organisation & Policy; 8).
  • Buvé A, Rogers MF. Epidemiology. AIDS 1998; 12(Suppl.A): S53-S54.
  • Cellier C, De Beenhouwer H, Berger A, Penna C, Carbonnel F, Parc R, Cugnenc PH, Le Quintrec Y, Gendre JP, Barbier JP, Portaels F. Mycobacterium paratuberculosis and Mycobacterium avium subsp. silvaticum DNA cannot be detected by PCR in Crohn's disease tissue. Gastroentérol Clin Biol 1998; 22: 675-678.
  • Clement J, McKenna P, van der Groen G, Vaheri A, Peters CJ. Hantaviruses. In: Palmer SR, Soulsby EJL, Simpson DIH, editors. Zoonoses; biology, clinical practice, and public health control. Oxford: Oxford University Press, 1998: 331-351.
  • Coggins C, Elias CJ, Atisook R, Bassett MT, Ettiègne-Traoré V, Ghys PD, Jenkins-Woelk L, Thongkrajai E, VanDevanter NL. Women's preferences regarding the formulation of over-the-counter vaginal spermicides [letter]. AIDS 1998; 12: 1389-1391.
  • Colebunders R, De Droogh E, Pelgrom Y, Depraetere K, De Jonghe P. Painful hyperaesthesia caused by protease inhibitors? [letter]. Infection 1998; 26: 250-251.
  • Colebunders R, Depraetere K, Van Wanzeele P, Van Gehuchten S. deafness caused by didanosine [letter]. Eur J Clin Microbiol Infect Dis 1998; 17: 214-215.
  • Coninx R, Pfyffer GE, Mathieu C, Savina D, Debacker M, Jafarov F, Jabrailov I, Ismailov A, Mirzoev F, de Haller R, Portaels F. Drug resistant tuberculosis in prisons in Azerbaijan: case study. Br Med J 1998; 316: 1423-1425.
  • Crabbé F, Tchupo JP, Manchester T, Gruber-Tapsoba T, Mugrditchian D, Timyan J, Goodridge G, Cheta C, Laga M, Dallabetta G. Prepackaged therapy for urethritis: the "MSTOP" experience in Cameroon. Sex Transm Infect 1998; 74: 249-252.
  • De Backer M, De Vroey C, Lesaffre E, Scheys I, De Keyser P. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol 1998; 38(Suppl.): S57-S63.
  • Delanghe JR, Langlois MR, Boelaert JR, Van Acker J, Van Wanzeele F, van der Groen G, Hemmer R, Verhofstede C, De Buyzere M, De Bacquer D, Arendt V, Plum J. Haptoglobin polymorphism, iron metabolism and mortality in HIV infection. AIDS 1998; 12: 1027-1032.
  • Diallo MO, Ghys PD, Vuylsteke B, Ettiègne-Traoré V, Gnaore E, Soroh D, Kadjo JC, Van Dyck E, De Cock KM, Greenberg AE, Laga M. Evaluation of simple diagnostic algorithms for Neisseria gonorrhoeae and Chlamydia trachomatis cervical infections in female sex workers in Abidjan, Côte d'Ivoire. Sex Transm Infect 1998; 74(Suppl.1): S106-S111.
  • Djajakusumah T, Sudigdoadi S, Meheus A, Van Dyck E. Plasmid patterns and antimicrobial susceptibilities of Neisseria gonorrhoeae in Bandung, Indonesia. Trans R Soc Trop Med Hyg 1998; 92: 105-107.
  • Elsen P, Meyers WM, Guédénon A, Guimaraes-Peres A, Fonteyne PA, Portaels F. Ulcère de Buruli: du nouveau? Les punaises aquatiques interviennent-elles dans l'épidémiologie de l'ulcère de Buruli en Afrique de l'Ouest? Bull ALLF 1998; (4): 22.
  • Ettiègne-Traoré V, Ghys PD, Maurice C, Hoyi-Adonsou YM, Soroh D, Adom ML, Teurquetil MJ, Diallo MO, Laga M, Greenberg AE. Evaluation of an HIV saliva test for the detection of HIV-1 and HIV-2 antibodies in high-risk populations in Abidjan, Côte d'Ivoire. Int J STD AIDS 1998; 9: 173-174.
  • Fransen K, Colebunders R, Heyndrickx L, Janssens W, van der Groen G. How many different HIV-1 viral load test kits do we need? [letter]. AIDS 1998; 12: 230-231.
  • Fransen K, Mertens G, Stynen D, Goris A, Nys P, Nkengasong J, Heyndrickx L, Janssens W, van der Groen G. Evaluierung eines neu entwickelten HIV-Anti-Gentest. J Club Highlights 1998; : 321-322.
  • Fransen K, Mortier D, Heyndrickx L, Verhofstede C, Janssens W, van der Groen G. Isolation of HIV-1 RNA from plasma: evaluation of seven different methods for extraction (part two). J Virol Methods 1998; 76: 153-157.
  • Frisk A, Ahmed HJ, Van Dyck E, Lagergard T. Antibodies specific to surface antigens are not effective in complement-mediated killing of Haemophilus ducreyi. Microb Pathog 1998; 25: 67-75.
  • Gerbase A, Noriega-Minichiello S, Vuylsteke B. Infections sexuellement transmissibles; le défi. Santé Monde 1998; 51(6): 10-11.
  • Gerbase A, Noriega-Minichiello S, Vuylsteke B. Sexually transmitted infections - the challenge. World Health 1998; 51(6): 10-12.
  • Ghys P. Control of HIV infection and other sexually transmitted diseases in female sex workers in Abidjan, Côte d'Ivoire [dissertation]. Antwerpen: Universitaire Instelling Antwerpen (UIA), 1998: 170 pp.
  • Gu XX, Rossau R, Jannes G, Ballard R, Laga M, Van Dyck E. The rrs (16S) - rrl (23S) ribosomal intergenic spacer region as a target for the detection of Haemophilus ducreyi by a heminested-PCR assay. Microbiology 1998; 144: 1013-1019.
  • Heeney JL, Teeuwsen VJ, van Gils M, Bogers WM, De Giuli-Morghen C, Radaelli A, Barnett S, Morein B, Akerblom L, Wang Y, Lehner T, Davis D. Beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc Natl Acad Sci U S A 1998; 95: 10803-10808.
  • Heeney JL, van Gils ME, Van der Meide P, De Giuli-Morghen C, Ghioni C, Gimelli M, Raddelli A, Davis D, Akerblom L, Morein B. The role of type-1 and type-2 T-helper immune responses in HIV-1 vaccine protection. J Med Primatol 1998; 27: 50-58.
  • Heyndrickx L, Janssens W, Coppens S, Vereecken K, Willems B, Fransen K, Colebunders R, Vandenbruaene M, van der Groen G. HIV type 1 C2V3 env diversity among Belgian individuals. AIDS Res Hum Retroviruses 1998; 14: 1291-1296.
  • Heyndrickx L, Janssens W, Gürtler L, Zekeng L, Loussert-Ajaka I, Vereecken K, Willems B, Coppens S, Ndumbe P, Fransen K, Saman E, Alary M, van der Groen G. Differential diagnosis of HIV type 1 group O and M infection by polymerase chain reaction and PstI restriction analysis of the pol gene fragments. AIDS Res Hum Retroviruses 1998; 14: 973-977.
  • Ishikawa K, Fransen K, Ariyoshi K, Nkengasong JN, Janssens W, Heyndrickx L, Whittle H, Diallo MO, Ghys PD, Coulibaly IM, Greenberg AE, Piedade J, Canas-Ferreira W, van der Groen G. Improved detection of HIV-2 proviral DNA in dually seroreactive individuals by PCR. AIDS 1998; 12: 1419-1425.
  • Johnson A, Laga M, Levy JA. [Editorial]. AIDS 1998; 12: i.
  • Kapiga SH, Vuylsteke B, Lyamuya EF, Dallabetta G, Laga M. Evaluation of sexually transmitted diseases diagnostic algorithms among family planning clients in Dar es Salaam, Tanzania. Sex Transm Infect 1998; 74(Suppl.1): S132-S138.
  • Kestens L, Vanham G. Environmental factors, the immune system and the susceptibility to infection. In: Greenwood B, De Cock K, editors. New & resurgent infections; prediction, detection and management of tomorrow's epidemics. Chicester: John Wiley, 1998: 71-86. (Dickens A, Ed. London School of Hygiene & Tropical Medicine, Annual Public Health Forums; 7).
  • Laga M, Schwartländer B. Epidemiology of AIDS in the developing world. In: Merigan TC, Bartlett JG, Bolognesi D, editors. Textbook of AIDS medicine; 2nd ed. Baltimore: Williams & Wilkins, 1998: 111-121.
  • Lankoandé S, Meda N, Sangaré L, Compaoré IP, Catraye J, Sanou PT, Van Dyck E, Cartoux M, Sankara O, Curtis V, Soudré RB. Prevalence and risk of HIV infection among female sex workers in Burkina Faso. Int J STD AIDS 1998; 9: 146-150.
  • Lankoandé S, Meda N, Sangaré L, Compaoré IP, Catraye J, Zan S, Van Dyck E, Cartoux M, Soudré R. L'infection à VIH chez les chauffeurs routiers au Burkina Faso: une enquête de séroprévalence. Méd Trop 1998; 58: 41-46.
  • Mayaud P, ka-Gina G, Cornelissen J, Todd J, Kaatano G, West B, Uledi E, Rwakatare M, Kopwe L, Manoko D, Laga M, Grosskurth H, Hayes R, Mabey D. Validation of a WHO algorithm with risk assessment for the clinical management of vaginal discharge in Mwanza, Tanzania. Sex Transm Infect 1998; 74(Suppl.1): S77-S84.
  • Meda N, Sangaré L, Lankoandé S, Compaoré IP, Catraye J, Sanou PT, Van Dyck E, Cartoux M, Soudré RB. L'épidémie à VIH au Burkina Faso: situation actuelle et niveau des connaissances de la population sur le sida, 1994-1995. Rev Epidémiol Santé Publique 1998; 46: 14-23.
  • Moherdaui F, Vuylsteke B, Siqueira LFG, dos Santos MQ, Jardim ML, de Brito AM, de Souza MCM, Willers D, Sardinha JCG, Benzaken AS, Ramos MC, Bueno H, Rodriques LGM, Chequer PJN. Validation of national algorithms for the diagnosis of sexually transmitted diseases in Brazil: results from a multicentre study. Sex Transm Infect 1998; 74(Suppl.1): S38-S43.
  • Ndoye I, Mboup S, De Schryver A, Van Dyck E, Moran J, Samb ND, Sakho ML, Thior I, Wade A, Heyman DL, Meheus A. Diagnosis of sexually transmitted infections in female prostitutes in Dakar, Senegal. Sex Transm Infect 1998; 74(Suppl.1): S112-S117.
  • Nkengasong JN, Willems B, Janssens W, Cheingsong-Popov R, Heyndrickx L, Barin F, Ondoa P, Fransen K, Goudsmit J, van der Groen G. Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing. AIDS 1998; 12: 1405-1412.
  • Nyambi PN, Gorny MK, Bastiani L, van der Groen G, Williams C, Zolla-Pazner S. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol 1998; 72: 9384-9391.
  • Ondoa P, Willems B, Fransen K, Nkengasong J, Janssens W, Heyndrickx L, Zekeng L, Ndumbe P, Simon F, Saragosti S, Gürtler L, Peeters M, Korber B, Goudsmit J, van der Groen G. Evaluation of different V3 peptides in an enzyme immunoassay for specific HIV type 1 group O antibody detection. AIDS Res Hum Retroviruses 1998; 14: 963-972.
  • Palomino JC, Obiang AM, Realini L, Meyers WM, Portaels F. Effect of oxygen on growth of Mycobacterium ulcerans in the BACTEC system. J Clin Microbiol 1998; 36: 3420-3422.
  • Palomino JC, Portaels F. Effects of decontamination methods and culture conditions on viability of Mycobacterium ulcerans in the BACTEC system. J Clin Microbiol 1998; 36: 402-408.
  • Pieniazek D, Baggs J, Hu DJ, Matar GM, Abdelnoor AM, Mokhbat JE, Uwaydah M, Bizri AR, Ramos A, Janini LM, Tanuri A, Fridlund C, Schable C, Heyndrickx L, Rayfield MA, Heneine W. Introduction of HIV-2 and multiple HIV-1 subtypes to Lebanon. Emerg Infect Dis 1998; 4: 649-656.
  • Portaels F. Basic microbiology. In: International Conference on Buruli Ulcer, Yamoussoukro, Côte d'Ivoire, 6-8 July 1998; abstract book. [s.l.]: [s.n.], 1998: 56-61.
  • Portaels F. Historical overview of Buruli ulcer. In: International Conference on Buruli Ulcer, Yamoussoukro, Côte d'Ivoire, 6-8 July 1998; abstract book. [s.l.]: [s.n.], 1998: 19-24.
  • Portaels F. L'ulcère de Buruli, une maladie émergente en Afrique; travail présenté pour le Prix SmithKline Beecham Pharma des Sciences Médicales d'Outre-mer 1998. [s.l.]: [s.n.], 1998: 162 pp.
  • Portaels F, Rigouts L, Realini L, Casabona NM, De Rijk WB, Jannes G, Kaustova J, Mijs W, Schulze-Röbbecke R, Tortoli E, Rossau R. Identification of mycobacterial species and subspecies by the INNO-LiPA Mycobacterium spp. test; evaluation of its usefulness for clinical and epidemiological studies. In: Casal M, editor. Clinical mycobacteriology. Barcelona: Prous Science, 1998: 117-124.
  • Portaels F, Traoré H, De Ridder K, Meyers WM. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother 1998; 42: 2070-2073.
  • Realini L. Study of optimal conditions for the in vitro growth of Mycobacterium genavense [dissertation]. Bruxelles: Université Libre de Bruxelles (ULB), 1998: 200 pp.
  • Realini L, De Ridder K, Palomino J, Hirschel B, Portaels F. Microaerophilic conditions promote growth of Mycobacterium genavense. J Clin Microbiol 1998; 36: 2565-2570.
  • Rieder HL, Chonde TM, Myking H, Urbanczik R, Laszlo A, Kim SJ, Van Deun A, Trébucq A. The public health service national tuberculosis reference laboratory and the national laboratory network; minimum requirements, role and operation in a low-income country. Paris: International Union against Tuberculosis and Lung Disease (IUATLD), 1998: 110 + div. pp.
  • Saidel TJ, Vuylsteke B, Steen R, Niang NS, Behets F, Khattabi H, Manhart L, Brathwaite A, Hoffman I, Dallabetta G. Indicators and the measurement of STD case management in developing countries. AIDS 1998; 12(Suppl.2): S57-S65.
  • Van Damme L, Niruthisard S, Atisook R, Boer K, Dally L, Laga M, Lange JMA, Karam M, Perriëns JH. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS 1998; 12: 433-437.
  • van der Groen G. Ebola en HIV als ambassadeurs van het regenwoud. Rainforest Med Bull 1998; 5(1): 5-6.
  • van der Groen G, Nyambi PN, Beirnaert E, Davis D, Fransen K, Heyndrickx L, Ondoa P, Van der Auwera G, Janssens W. Genetic variation of HIV type 1: relevance of interclade variation to vaccine development. AIDS Res Hum Retroviruses 1998; 14(Suppl.3): S211-S221.
  • Van Deun A, Portaels F. Limitations and requirements for quality control of sputum smear microscopy for acid-fast bacilli. Int J Tuberc Lung Dis 1998; 2: 756-765.
  • van Soolingen D, van der Zanden AGM, de Haas PEW, Noordhoek GT, Kiers A, Foudraine NA, Portaels F, Kolk AHJ, Kremer K, van Embden JDA. Diagnosis of Mycobacterium microti infections among humans by using novel genetic markers. J Clin Microbiol 1998; 36: 1840-1845.
  • Van Tendeloo VF, Snoeck HW, Lardon F, Vanham GL, Nijs G, Lenjou M, Hendriks L, Van Broeckhoven C, Moulijn A, Rodrigus I, Verdonk P, Van Bockstaele DR, Berneman ZN. Nonviral transfection of distinct types of human dendritic cells: high-efficiency gene transfer by electrophoration into hematopoietic progenitor- but not monocyte-derived dendritic cells. Gene Ther 1998; 5: 700-707.
  • Vandercam B, Gala JL, Gerain J, Degraux J, Bourlond A, Colebunders R, Pirard C, Portaels F. About two cases of Mycobacterium simiae infection in AIDS: review of the pathogenicity. Acta Clin Belg 1998; 53: 206-212.
  • Vanham GL, Penne L, Vereecken C, Vingerhoets J, Kestens L. Interleukin-2 receptor subunit expression and function on human peripheral T cells is not dependent on the anticoagulant [letter]. Blood 1998; 92: 2989-2992.
  • Vingerhoets J, Bisalinkumi E, Penne G, Colebunders R, Bosmans E, Kestens L, Vanham G. Altered receptor expression and decreased sensitivity of T-cells to the stimulatory cytokines IL-2, IL-7 and IL-12 in JIV infection. Immunol Lett 1998; 61: 53-61.
  • Vingerhoets J, Dohlsten M, Penne G, Colebunders R, Sansoms D, Bosmans E, Kestens L, Vanham G. Superantigen activation of CD4+ and CD8+ T cells from HIV-infected subjects: role of costimulatory molecules and antigen-presenting cells (APC). Clin Exp Immunol 1998; 111: 12-19.
  • Vingerhoets J, Michielsen P, Vanham G, Bosmans E, Paulij W, Ramon A, Pelckmans P, Kestens L, Leroux-Roels G. HBV-specific lymphoproliferative and cytokine responses in patients with chronic hepatitis B. J Hepatol 1998; 28: 8-16.
 


Tél.: +32 3 247.66.66 - Fax: +32 3 216.14.31 - Courriel:info@itg.be
Nationalestraat 155 - B-2000 Antwerpen

© 2001-2007 ITG - All Rights Reserved

Created by All Directions